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Abstract
The revolutionary development of soft ionization techniques like matrix-assisted laser
desorption/ionization (MALDI) has opened up the possibilities for mass spectrometry (MS) in
protein detection, identification, and sequencing. The ability of MALDI MS to acquire images
of intact tissue sections offer an additional dimension of analysis where location information
can be attained. Visualization of biological systems help to unravel the complexities of cells,
drug pathways, and disease pathology. However, the capabilities of MALDI MS imaging are
often being questioned, as signals are typically biased towards the most abundant component
within a complex sample. Within biological tissue samples, the most abundant components are
salts and lipids making it difficult for compounds such as proteins and peptides to ionize and
be detected.

In this thesis, sample preparation techniques are investigated to help improve the detection
sensitivity of MALDI MSI for proteins and peptides through investigation of ZP1609 and the
amyloid ß (Aß) protein. ZP1609 is an antiarrhythmic drug designed to protect against cardiac
ischemia-reperfusion injury, and Aß oligomers are strongly correlated with Alzheimer’s
disease (AD) pathology. Both of which are considered lower abundance compounds within
samples analyzed, and therefore ideal candidates for the work described herein. This thesis
presents MALDI MS capabilities in the detection of noncovalent complexes by distinguishing
variations in in vitro Aß composition for different sample preparatory procedures.
Furthermore, a reduction in ion suppression effects by salts and lipids was demonstrated with
increased MALDI MSI detection sensitivity for the target peptide. Most noticeably, an
i

additional acidification protocol generated images of greater detection sensitivity, and spatial
resolution. Introduction of solid-phase extraction (SPE) by means of magnetic bead application
was designed to improve the extraction of proteins from tissue sections. The C18
functionalized magnetic beads provided signal enhancement capabilities for varying
concentrations of Aß1-42 samples, however difficulties were encountered when applied for
MALDI MSI analysis. Nonetheless, the application of SPE for targeted analyte extraction prior
to MALDI MS analysis was beneficial in improving detection sensitivity of Aß proteins with
and without the presence of contaminants from tissue sections.

Keywords
MALDI TOF MS, MALDI MSI, Alzheimer’s disease, amyloid beta oligomers, matrix
application, detection sensitivity, protein imaging, peptide imaging, solid-phase extraction,
magnetic beads.
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Chapter 1: Introduction of Mass Spectrometry in
Protein and Peptide Analysis
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1.1 Overview of Protein Analysis
1.1.1 Amino Acid Building Blocks

As building blocks of cellular systems, proteins play a critical role in the structure, function,
and regulation of biological systems. They are comprised of 20 naturally occurring amino
acid residues with molecular weights ranging from 57 – 186 Da. These residues group
together to form polypeptide chains predetermined by the genetic code. As indicated in
Table 1.1, amino acids can be classified as either polar, or nonpolar based on the side chain
composition [1-3]. Having awareness of the polarity of each residue helps to understand
the hydrophobicity of amino acids, and in turn, predict the resulting protein structure.
However, there is controversy surrounding the level of hydrophobic properties each residue
possesses. Variations exist because of the difference in methods used to assess the relative
hydrophobicity of each amino acid residue [4-7]. The measure of hydrophobicity is often
achieved through either examination of the 3D protein structure, or by looking at the
physical properties of the sidechains and observing how the amino acid partitions in water
versus nonpolar solvent environments. Differences in the results obtained occurs when two
different methods are used. Since the former evaluates the amino acid as part of a
polypeptide chain, while the latter looks at the free amino acid residues, the two methods
yield different results for residues that possess levels of opposing properties. In addition to
the differences in evaluation, hydrophobic properties of the 20 amino acid residues is a
relative unit of measure. Alternative factors such as the surrounding environment also play
a role in the hydrophobicity of the amino acid. The polarity and hydrophobic properties of
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cysteine and tyrosine at times are a topic of controversy. Cysteine possesses an –SH group
which makes it a polar amino acid residue, but when investigating the 3D structure of
proteins, cysteine is often found embedded within the core of the protein leading to
misinterpretation that it is hydrophobic. However, this behaviour can be a result of the
residue’s affinity to form disulfide bonds found in the core of the protein. Alternatively,
tyrosine is an aromatic amino acid, and therefore should be considered nonpolar [2, 8].
Despite the aromatic ring, tyrosine also possesses an- OH group, and its contributions
towards hydrogen bonding causes conflicting results when the level of hydrophobicity is
assessed in different environments. For the purposes of the work described here, both
cysteine and tyrosine will be regarded as a polar amino acid residues.
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Table 1.1 Amino acid residues are listed with both the 3- and 1- letter symbols associated
with each. The polarity of each amino acid has been provided.

Alanine

3-Letter
Symbol
Ala

1-Letter
Symbol
A

Nonpolar

Arginine

Arg

R

Polar

Asparagine

Asn

N

Polar

Aspartic Acid

Asp

D

Polar

Cysteine

Cys

C

Polar

Glutamic Acid

Glu

E

Polar

Glutamine

Gln

Q

Polar

Glycine

Gly

G

Nonpolar

Histidine

His

H

Polar

Isoleucine

Ile

I

Nonpolar

Leucine

Leu

L

Nonpolar

Lysine

Lys

K

Polar

Methionine

Met

M

Nonpolar

Phenylalanine

Phe

F

Nonpolar

Proline

Pro

P

Nonpolar

Serine

Ser

S

Polar

Threonine

Thr

T

Polar

Tryptophan

Trp

W

Nonpolar

Tyrosine

Tyr

Y

Polar

Valine

Val

V

Nonpolar

Amino Acid

Polarity
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1.1.2 Protein Structure

Amino acids join together through a condensation reaction with the amino group of one
amino acid, and the carboxyl group of the other. This reaction releases water, forming the
backbone of polypeptide chains. This unique backbone has minimal intrinsic mobility due
to the partial double bond characteristics it possesses [2, 9]. The α-helical or ß sheet
secondary structure of a polypeptide chain is generated through intra- and inter-strand
hydrogen bonding respectively. The α helix conformation is developed when hydrogen
bonding occurs between the carbonyl and the amino group of an amino acid four residues
away in the polypeptide sequence [10]. The ß sheet structure is generated when hydrogen
bonding occurs between the NH and CO groups of amino acids in different polypeptide
chains. The formation of ß sheets can be in both anti-parallel or parallel orientations.

After formation of the secondary structure, these proteins then fold and bend to form the
three dimensional tertiary structure. At this stage, structural formation is determined
primarily from the amino acid sequence. However, the protein’s environmental
surroundings also play a key role in structural formation. Proteins will acquire the tertiary
structure which provides the greatest stability, and in turn, the lowest energy state. In
general, amino acids with hydrophobic side-chains will be buried within the protein
structure, while the polar amino acids reside on the surface. In comparison to the secondary
form, the tertiary structure of proteins appear to be irregular and unstructured. However,
these three dimensional formations are developed and stabilized by the interactions
between amino acid side-chains, and the hydrophobic backbone [11-12]. These interactions
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include, hydrogen bonding, and the formation of salt or disulfide bridges. Protein
quaternary structures then reflect the interaction between globular protein subunits which
aggregate and develop into larger protein complexes.

1.1.3 Biological Functions & Interactions of Proteins

Based on just 20 different amino acid building blocks, countless proteins that serve key
roles in structure, function and transport for all biological systems are generated. They can
be categorized as antibodies, assembly proteins, blood proteins, enzymes, hormones,
membrane proteins, or nucleoproteins. In attempts to understand biological systems, a
growing list of protein interactions continue to be uncovered year after year. The majority
of protein interactions are identified as protein-protein interactions (PPI), but interactions
also exist between protein-lipids (often involving membrane proteins), and proteins with
carbohydrates.

Studying PPI can help researchers in furthering the understanding of protein function. The
nature of the interaction differs depending on the protein affinity, composition, as well as
whether the interaction is permanent or transient [13]. The key driving force in these
interactions involve the protein concentration within a system, and the free energy of the
complex in comparison to the energy of the protein in alternative states. PPI can be
distinguished based on the structural and functional groups of the proteins involved, and
the physical characteristics of the interaction. Complexes are considered either obligate, or
non-obligate [13-14]. Where the former does not exists in vivo as stable structures, and the
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latter can be found in vivo as stable, independent complexes. Alternatively, protein
interactions are also classified as transient or permanent based on the lifetime of the
resulting complex. Aside from PPI, lipid-protein interactions encompass another division
that is integral in the functionality of biological systems as a whole. Lipids play a key role
in the unique functionality, and physical properties of cellular membranes [15-17]. This
type of interaction can be characterized as integral membrane proteins, peripheral
membrane proteins, and soluble protein interactions [18-21].

1.2 Protein Analysis
Understanding the physical and chemical properties of proteins helps to elucidate
biological systems and processes. This investigation involves identifying the molecular
weight of proteins, studying the amino acid sequence, analyzing the 3D structure,
understanding protein interactions, and to obtain location information for the presence of
proteins within a biological tissue sample. Since protein functions are highly dependent on
their structure, the study of intact proteins has become a primary target for many
researchers [22-24]. With advancements in analytical techniques, researchers are now able
to study intact protein structures, expression, and interactions. This information can aid the
understanding of disease pathology to facilitate the development of therapeutics, detection
of disease development, and possible preventative measures.

Continuous development in analytical techniques provided additional platforms for the
investigation of protein characteristics. X-ray crystallography, nuclear magnetic resonance
(NMR), and electron microscopy are popular methods for the anlaysis of the 3D structure
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of proteins. Alternatively, chemical crosslinking, fluorescence resonance energy transfer
(FRET), and protein arrays are often used for studying protein interactions [25-31].
Proteomic research is an exponentially growing field of study, continuously expanding
based on the development of available techniques. A large area of interest resides in protein
identification within biological systems through the separation and detection of proteins
based on molecular weight and sequencing. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and mass spectrometry are commonly used techniques in the
separation and identification of proteins. SDS-PAGE is capable of isolating target proteins
or peptides using electrophoresis. Application of SDS denatures the protein sample while
providing an environment with a negative net charge. The proteins within the mixture then
separate as they travel towards the anode. The negative environment disrupts the complex
structures of proteins so the rate at which proteins travel is predominantly based on the
molecular mass of the polypeptide.

SDS-PAGE is an effective technique in identifying proteins for targeted approaches,
however mass spectrometry (MS) provides a method to perform targeted and untargeted
analysis of a wide range of molecules. This technique only requires microliter amounts of
sample for analysis, and does not need the addition of dyes or antibodies for detection.
Conventional ionization techniques, chemical ionization (CI), electron ionization (EI), and
fast atom bombardment (FAB) limited MS to small, thermostable compounds. These
ionization techniques resulted in severe fragmentation of relatively larger molecules which
generated complex spectra that is difficult to interpret. In the late 1980s, development of
two ionization techniques, electrospray ionization (ESI) and matrix-assisted laser
desorption/ionization (MALDI) made MS available for analysis of larger molecules such

30

as proteins [22]. These two ionization techniques reduces the fragmentation of larger
molecules, and therefore retains the original, intact molecule during the ionization process
making it possible to directly study larger peptides and even intact proteins.

The development of imaging techniques provided a methodology to obtain location
information for target proteins. Traditionally, staining and labelling techniques such as,
immunohistochemistry (IHC), magnetic resonance imaging (MRI), fluorescence
microscopy, and positron emission tomography (PET) were used for targeted identification
of proteins within biological systems. Although effective, these techniques are dependent
on the successful staining or labelling of target molecules, and therefore successful
localization of these proteins are directly affected by the specificity of the stains and labels
used.

Introduction of matrix-assisted laser desorption/ionization mass spectrometry imaging
(MALDI MSI) presented a powerful technique which provides two dimensional
information regarding target samples. This platform is not only capable of the
characterization and identification of proteins and complex molecules, but it also possesses
the ability to map out protein expression within intact tissue sections. Similar to standard
MALDI MS analysis, information is extracted as the laser hits the matrix coated sample.
As the laser moves along the tissue section, each ablation spot allows for information to be
extracted and acts as “pixels” for the image generated. This method of analysis provides
information regarding protein expression within a biological sample, which would
typically be lost in standard protein extraction, purification or separation protocols.
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1.3 Theory and Instrumentation for Mass Spectrometry
1.3.1 Instrumentation for Mass Spectrometry

Mass spectrometry has come a long way since the development of the first instrument by
Sir J. J. Thomson [32-33]. As the instrument matured, its capabilities continues to expand
beyond a tool for physicists. From initially detecting the charge-to-mass (e/m) for particles
such as electrons, to the ongoing expansion of applications in all fields of science. Overall,
three processes occur in mass spectrometers, ion generation, separation, and detection.
These three processes are achieved using an ion source, mass analyzer, and the ion detector
respectively.

The ion source is where sample ions are generated. A variety of ionization sources are
available, with the most prominent ones in proteomic research being electrospray
ionization (ESI), and matrix-assisted laser desorption/ionization (MALDI). These “soft”
ionization systems produce ions with minimal fragmentation, therefore providing intact
gaseous sample ions for analysis of larger biomolecules. The ions generated are then
transferred to the mass analyzer, where they are separated based on their mass-to-charge
ratios (m/z). The five most commonly use mass analyzers are, time-of-flight (TOF),
quadrupole (Q), quadrupole ion trap (QIT), orbitraps, and fourier-transform ion cyclotron
resonance (FT-ICR) [34]. Analyzer selection is decided by the necessary sensitivity,
resolution, mass accuracy, and mass range to encompass specifications required for the
target analysis.
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In mass spectrometry, sensitivity refers to the ratio of the maximum number of ions
recorded at a given m/z (of M) to the signal of the background at an adjacent m/z (of M +
1) [35]. It takes into account the relationship between maximum useable signals acquired,
versus the minimum useable signal (detection limit). Although detection sensitivity of the
mass analyzer can provide a relative indicator of the maximum discernable concentrations
of analyte within a sample, detection of low abundance components within a sample is also
dependent on other factors such as the instrument’s resolving power. A mass spectrometer’s
resolving power is the ability of the mass analyzer to effectively separate, define, and
generate two distinct signals from components within a mixture with minor differences in
m/z. Simply put, the narrower the peak, the higher the resolution. The resolution (R) for a
single peak can be measured with,

𝑅=

𝑀
∆𝑀

(Eq. 1.1)

Where M as the peak position (m/z), and ΔM is the width of the peak at the position of 50%
peak height [36]. Resolving power becomes increasingly important when performing
untargeted analysis, and when characterizing molecules with near identical masses. Mass
accuracy in MS refers to the error in mass measurement. It evaluates the difference between
measured, and actual m/z values of the target analyte. This measurement is usually provided
in parts per million (ppm), and is calculated by dividing the difference of observed and true
m/z values, by the true m/z of the analyte. The mass accuracy of a analyzer is directly
correlated with its resolving power. Therefore, the higher the mass resolution, the greater
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the mass accuracy. The mass range refers to the range of m/z for which the analyzer can
detect ions with sufficient resolution to differentiate between adjacent peaks. For many
analyzers, increasing the mass range results in compromise with the signal detection of
lower m/z ions, therefore the upper limit is a relative maximum, at which point the
instrument performance becomes severely compromised.

Different analyzers possess different mass range capabilities, and this is often the limiting
factor when deciding upon a suitable instrument for analysis. For quadrupole mass
analyzers, m/z selection is achieved through variations in the magnitude of radio frequency
(RF), and the direct current (DC) applied to the four electrode rods [37-38]. The application
of RF and DC determines the trajectory of the ions passing through, allowing for ion mass
selection or identification. Ions with unstable trajectories are eventually neutralized
through collision with the quadrupole electrode rods. These analyzers provide good
reproducibility, but is limited with the resolution obtained. In conjunction with an ion trap,
QIT mass analyzers possess a similar mechanism for m/z selection, however instead of the
stable ion being selected, mass selection for QIT is achieved through ion instability [35,
39]. In QIT mass analyzers, a three dimensional electric field is applied, which effectively
traps the ions. As the RF increases, ions with higher m/z are ejected. The manipulation of
DC and RF voltages allow for extensive MS/MS analysis of high resolution and sensitivity.
Orbitraps contains a spindle-like inner electrode and a barrel-like outer electrode. As the
voltage applied increases, ions are introduced into the trap. The ions oscillate along the
horizontal axis of the inner electrode and m/z selection is achieved as ions of differing m/z
reach the desired orbit within the trap. FT-ICR analyzers operate based on the same
mechanism as QIT by storing ions and selecting m/z through manipulation of voltages
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applied [39]. However, the ions travel in a circular path within a magnetic field. The ion
mass can then be determined by detection of the cyclotron frequency for the ion’s circular
motion. Among the available mass analyzers, FT-ICR provides the highest level of mass
resolution, but possesses a limited mass range. For TOF mass analyzers, the ion mass is
determined by measuring the amount of time it takes to travel through a flight tube. TOF
mass analyzers are extremely fast, and provide a high mass range. Therefore, TOF mass
anayzers are very desirable for targeted and untargeted protein analysis.

1.3.1.1 Principles of Time-Of-Flight Mass Analyzers

Decades after J. J. Thomson constructed the first spectrometer, time-of-flight (TOF) mass
analyzers were introduced [33, 40]. TOF mass analyzers were conceptualized in 1946,
however the first commercial TOF analyzer was not introduced until the 1950s. The mass
analyzer promoted was based on designs by William Wiley, and I. H. McLaren. At this
time, the attainable resolution was so poor that the technique was not viable for MS
applications. Improvements in the resolution of TOF analyzers wasn’t possible until the
development of reflectron by Boris Mamyrin. From then on, TOF analyzers continued to
improve in resolution, and developed into an indispensible tool for mass spectrometry.

TOF analyzers separate ions based on their mass, and measures the mass-dependent time
required for the ions to travel through the drift tube to the detector. To start, ions generated
in the “plume” are released from the source in sets, these ions with mass, m, and a charge
of q = ze, are collected in an acceleration region until max capacity is reached [34, 41].
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Once full, a difference of potential applied between the sample plate and an extraction grid
accelerates the ions towards the drift tube. Since the kinetic energy acquired by each ion is
equal, separation of the ions result solely from the ion mass. High mass ions will possess a
lower velocity in comparison to smaller mass ions. The ion velocity is then recorded based
on the amount of time it takes for the ions to reach the detector. With the known length of
the flight tube, and the measured ion velocity, mass-to-charge can then be calculated with
the equation,

1
𝑧𝑒𝑉 = 𝑚𝑣 2
2

(Eq. 1.2)

2𝑧𝑒𝑉
𝑣= √
𝑚

(Eq. 1. 3)

𝑚
2𝑒𝑣
= 𝑡 2( 2 )
𝑧
𝐿

(Eq. 1. 4)

Here, m/z represents the mass-to-charge ratio of ions, t and v represent the time required
for ions to reach the detector, and the velocity of the ions respectively [34]. Lastly, L is the
length of the flight tube in which the ions travel through. From the equations above, ions
with different m/z values will travel at different velocities, and therefore reach the detector
at different times (Eq. 1. 4). With velocity in consideration, the ions can either be positively,
or negatively charged depending on the voltage polarity used.
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The mode of analysis outlined above directly measures the amount of time required for
ions to travel through the flight tube and reach the detector. With TOF mass analyzers, this
mode is categorized as the linear mode of analysis. However, when ions are formed in the
desorption plume, differences in initial kinetic energies exist. These differences result in a
corresponding shift of arrival times at the detector for ions of the same mass which
contributes to a decrease in mass resolution. In order to compensate for these shifts, a
delayed extraction (DE) technique can be applied [42]. This delay permits the ions
generated within the plume to expand into a field-free region in the source. The electric
field applied remains consistent between the sample plate and the extraction grid. As a
result, ions with higher initial kinetic energy will move further away from the sample plate
in comparison to those with lower kinetic energies. After the delay, the ions are accelerated
through the flight tube, where the high energy ions will experience less of a potential
difference than the low energy ions. This allows ions of the same mass to eventually reach
identical velocities as they travel towards the detector. Alternatively, the reflectron mode
can be used to reduce effects of variations among initial energy distribution for ions
generated. In reflectron mode, a series of parallel mirrors with a voltage gradient are used
to slow, and turn ions onto a second flight path towards the detector [36]. This allows ions
with greater kinetic energy to penetrate deeper and travel a further distance prior to
redirecting towards the detector (Figure 1.1). As a result, ions of the same mass with
varying initial kinetic energy will arrive at the detector simultaneously, hence improving
the mass resolution obtained.
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Figure 1.1 Schematics for both linear (A) and reflectron (B) modes of MALDI TOF mass
analyzers.
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1.3.1.2 Applications of TOF Analyzer

TOF analyzers are now one of the most commonly used mass analyzers for MALDI MS.
In theory, TOF possesses an unlimited mass range since ion trapping is not applied, and
linear flight paths are used. However, in practice the detector restricts detection efficiencies
to within a few hundred kDa mass range. Even with the confines of the detector, TOF
analyzers provide a high practical mass range in comparison to other available mass
analyzers [36]. TOF also has high levels of detection sensitivity, and remains the fastest
MS analyzer available. This analyzer possesses good levels of mass accuracy, and its
construction is comparatively inexpensive to other analyzers.

The high mass range TOF analyzers are capable of, in conjunction with the high signal
resolution, sensitivity, and mass accuracy, these analyzers provide the ideal parameters for
protein analysis. When used in MALDI MS systems, the soft ionization method provides
data regarding the molecular mass of polypeptides, while the MS/MS capabilities offer an
additional dimension of analysis. Upon selection of a precursor ion, the amino acid
sequence, and post translational modifications of protein samples can be identified.
However, advantages of TOF analyzers are strongly limited by the capabilities of the
detector employed.
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1.3.1.3 Detectors

All mass spectrometers aside from orbitraps and fourier-transform ion cyclotron resonance
(analyzer acts as a detector as well) requires a detector [43]. The detectors record the ion
intensities of each m/z value, and records the data electronically in the form of a mass
spectrum [44]. Depending on the type of detector used, the resulting signals are produced
by either generating secondary electrons, which are then further amplified, or by inducing
a current using a moving charge [36]. Commonly used detectors for MS include, Faraday
cup, electron multiplier (EM), and photomultiplier (or scintillation counter). The role of
the detector is to be able to identify the abundance of ions present per m/z. The information
obtained is then converted for computer based data storage, and processing in order to
convey the data in the form of a spectra [45]. With continued development in the realm of
ionization and separation for MS analysis, the demand for advancements in detection
technology has become more critical. Although improvements in existing detection
capabilities have been observed, these changes have been minimal in comparison to the
developments made in the technology for mass analyzers. Ideally, MS detectors need to be
consistent with ion-detection efficiency, possess minimal to no noise, capable of
simultaneous detection of multiple ions, possesses a wide mass and dynamic range, short
recovery time, and a high saturation level [44]. Ion detection efficiency, and level of noise
present for detectors are limiting factors in obtaining high mass accuracy and sensitivity in
MS measurements. The level of noise present can be a result of multiple sources, noise can
be generated within the detector itself, or from supporting electronic sources. Techniques
capable of minimizing effects of noise are, signal filtering, and time averaging. Although,
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no single detector stands superior in all characteristics, choice of detector employed is
determined by the needs of the analyzer. Detector selection for TOF mass analyzers
prioritize a broad mass range, mass accuracy, minimal recovery time, and capabilities of
simultaneous ion detection. Due to rapid operations of TOF mass analyzers, detectors used
must be capable of simultaneous detection of multiple ions, and a short recovery time.

1.3.2 Soft Ionization Methods

1.3.2.1 Electrospray Ionization (ESI)

In response to the rising demand of biological applications for mass spectrometry, “soft”
ionization methods were developed. Electrospray ionization (ESI) was first conceptualized
in the 1960s by Malcolm Dole, but it wasn’t until 20 years later that ESI was first applied
for biomolecule analysis by John Fenn [33]. In ESI, there are three major steps in order to
generate gas-phase ions, solvent introduction, solvent evaporation, and finally
development of charged gaseous ions [46]. ESI is an atmospheric technique where sample
solutions flow continuously (nL / min to µL/min) through a metal capillary needle held at
an electric potential [46-50]. As an electric field is imposed on to the liquid sample, an
enrichment of like charged ions occur near the cone. This potential difference between the
capillary and the surrounding environment causes a dispersion of charged sample droplets
in the form of a fine mist. The droplets then travel downfield towards the opposing
electrode. During this process, exposure to the inert gas in the environment promotes
solvent evaporation. As the solvent evaporates, the growing charge density results in an
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increase in repulsion between the charges. The buildup of repulsion is eventually enough
to overcome surface tension of the droplet, and coulomb fission occurs. This process
continues with the parent droplets leading to secondary fissions, which eventually
generates charged gas-phase ions. These ions are then introduced into the mass analyzer
for separation and detection.

ESI generally produces multiply charged ions, therefore it is able to enhance the
capabilities of mass spectrometers with limited mass range to be applicable in the analysis
of larger analytes. However, in order for successful detection of larger molecules, the
instrument must possess high resolving powers to differentiate between peaks of multiply
charged ions. ESI MS has minimal tolerance for contaminants such as salts or detergents
which can cause adduct formation with proteins or compete with target analytes for
ionization [46]. Therefore, ESI MS is typically coupled with on-line liquid chromatography
(LC) to separate components within a complex mixture prior to MS analysis.
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Figure 1.2 Illustration of an ESI ion source in positive mode. An electric field is imposed
on the sample liquid, resulting in a build-up of positive ions near the cone. The potential
difference between the capillary and the environment results in a dispersion of positively
charged sample liquid in the form of a mist. As the solvent evaporates, the charge repulsion
within each droplet builds up and eventually causes coulomb fission to occur.
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1.3.2.2 Matrix-Assisted Laser Desorption/Ionization (MALDI)

Matrix-assisted laser desorption/ionization (MALDI) was first introduced by Franz
Hillenkamp and Michael Karas in 1988 [36]. Over the past 30 years, MALDI has
developed into a technique that is applicable to various scientific fields, including
chemistry, biochemistry, biology, and even in clinical settings. While ESI converts liquid
phase analytes to gas phase ions for analysis, MALDI converts solid phase analytes to gas
ions. This technique generates primarily singly charged molecules, and has a higher
tolerance against contaminants in comparison to ESI. This makes MALDI MS a valuable
tool for untargeted research of complex biological systems.

In the MALDI MS process, analyte molecules are embedded in the crystalline structure of
a small organic compound called the matrix. This mixture is then deposited onto a MALDI
target plate. Once dried, the sample is introduced into the mass spectrometer, where the
sample-matrix mixture is irradiated by a UV laser pulse (typically of wavelengths 337 nm
and 355 nm). The laser causes heat production at the target plate, resulting in localized
sublimation and ultimately ionization of the sample-matrix mixture releasing the molecules
into the gas phase [51]. Both ions and neutral molecules are generated from this process,
but only the ions are accelerated by the electric field towards the analyzer for separation
followed by detection.

MALDI matrix selection is extremely important in order for successful detection of target
analytes. Although guidelines are available for the most common matrices, definitive
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selection of a suitable matrix is still a process of trial-and-error as a result of the
uncertainties with the mechanism of the ionization process. Ionization of target samples
with MALDI is a two part process, first the matrix must be ionized, and this is followed by
an ion-molecule reaction to generate charged analyte ions [36, 52-53]. Several models have
been proposed in attempts to elucidate the phenomenon, but it is highly unlikely to generate
a model that can encompass the range of parameters that may affect the ionization
environment. Among the proposed mechanisms, the most widely accepted hypothesis
involves a gas-phase transfer of protons from matrix to analyte. In this model, matrix ions
are generated in the primary ion formation, resulting in an expanding matrix “plume”. A
secondary ionization then occurs as a proton transfer takes place between the matrix and
analyte thereby desorbing and ionizing the analyte molecules [54].

Since its conception, MALDI MS has become a well established technique in the analysis
of a wide range of samples, including proteins, peptides, oligonucleotides, polysaccharides,
lipids, synthetic polymers, and inorganics. Among its applications, MALDI MS has been
most prominent in the analysis of peptides and proteins since they have a much higher
proton affinity (10-3 – 10-4) in comparison to analytes like carbohydrates (10-7 – 108) [5559].

45

1.4 Application of MALDI Mass Spectrometry
1.4.1 Role of MALDI Matrices

Overall, there is a general consensus in the significance of MALDI matrices in the entire
ionization process, however controversy exists in the ionization mechanism. A suitable
mechanism should be able to explain the presence and abundance of all the ions generated,
but so far none of the proposed mechanisms are capable. It is also extremely difficult to
generate one hypothesis which can encompass the range of experimental and instrumental
conditions which may affect the ionization of the matrix-analyte mixture. The controversy
primarily surrounds the initial ionization of the matrix molecule. However, there are higher
levels of acceptance regarding the proposed mechanism in which secondary ionization
generates charged analyte ions. During this secondary ionization process, proton transfer
occurs between the matrix and the analyte [51, 53]. The matrix acts as both a proton donor
and acceptor facilitating the generation of ions in both positive and negative modes,
respectively. During this process, energy resulting from this transfer is also received by the
analyte. The level of energy that is transferred directly influences the degree of in source
fragmentation that occurs [60]. Different matrices transfer different degrees of energy
during this process, matrices that provide a greater energy transfer are considered “hot”
matrices, while lesser energy transfer indicates the matrix is “cold” [42]. The matrix also
plays a protective role in shielding the analyte from the initial laser irradiation, and
therefore minimizes undesirable fragmentation making MALDI a “soft” method of
ionization.
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1.4.2 MALDI Matrices and Deposition Methods

Several criteria must be met for MALDI matrices to effectively ionize the target samples.
Most commonly used matrices are solid, organic acids. However, continuous investigation
into effective, novel materials have shown success in use of liquid matrices, and solid
micro/nano particles. Matrices must also be readily soluble in commonly used sample
preparatory solvents (eg. acetonitrile, ethanol, methanol etc.), relatively stable in a vacuum
environment, provide a homogenous matrix-analyte deposit, and possesses strong UV
absorbing capabilities at the laser wavelength.

The three most commonly used matrices are, 2, 5-dihydroxybenzoic acid (DHB), α-cyano4-hydroxycinnamic acid (CHCA), and sinapinic acid (SA). The latter two are
predominantly used for peptide and protein analysis respectively [61]. The structures of
each have been shown in Figure 1.3. DHB has a molecular weight of 154.12 g/mol, and it
is capable of absorbing UV wavelengths of 266 nm, 337 nm, and 355 nm. Among the three
standard matrices, DHB produces less background signals from matrix clusters. Therefore,
this matrix is suitable for analysis of the lower m/z range, where signals from matrix
clusters are often observed. DHB is considered a “cold” matrix, therefore minimal loss of
neutral groups attached to the protein backbone during the ionization process occurs [62].
As a result, DHB is commonly used for the study of proteins with post translational
modifications (PTMs), phosphopeptides, and glycoproteins.
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Figure 1.3 The structure of three commonly used matrices in MALDI MS have been
shown. All three matrices are small, organic acids consisting of an aromatic ring. Each
matrix possesses UV absorbing capabilities in the 337 nm, and 355 nm wavelengths.
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CHCA has a molecular weight of 188.16 g/mol, and it is widely used to facilitate ionization
of peptides or small proteins with a molecular mass of < 10,000 Da. CHCA matrix
generates a homogenous matrix-analyte deposition, which contributes to a high shot-toshot reproducibility making it very effective in peptide mass fingerprinting. This matrix
absorbs UV at both 337 nm and 355 nm wavelengths, and is readily soluble in polar
solvents. Successful application of CHCA has also been reported for lipid and nucleotide
analysis, but it is important to note that this matrix generates numerous peaks within the
100 - 400 m/z region . CHCA is also effective in the detection of low concentration protein
digests using MALDI-TOF MS.

SA has a molecular weight of 224.21 g/mol, and is mostly used in the positive mode of
analysis. Like DHB, it is considered a “cold” matrix, and capable of absorbing UV
wavelengths of 266 nm, 337 nm, and 355 nm. SA can be applied to peptide analysis, but
generally it excels in the detection of intact proteins because of the lesser degree of insource fragmentation observed [63]. Continuous development of potential MALDI
matrices have generate several alternative compounds which have shown to be effective in
facilitating ionization in MALDI MS. These compounds, dihydroxyacetone phosphate
(DHAP), 1, 5 – diaminonaphthalene (DAN), 2, 4, 6 – trihydroxyacetophenone (THAP),
and 2 – (4 – hydroxyphenylazo)benzoic acid (HABA) along with the primary analytes they
target have been listed in Table 1.2.
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Table 1.2 Alternative matrices developed for MALDI MS analysis, and the target analyte
of interest each matrix is most successfully used for have been listed. Unfortunately, as a
result of the uncertainties with the ionization mechanism, these are all simply guidelines
when choosing a matrices for experiments. The guidelines help to narrow down the
selection, however trial-and-error is required to determine the optimal selection for the
target analyte.

DHAP

DAN

Glycoproteins
Complex Protein Profiling
Gangliosides
Oligonucleotides

THAP

HABA

X

X

X
X
X

Glycolipids

X

Synthetic Polymers

X
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Sample preparation methods are another factor that greatly effects signal detection.
Standard MALDI MS samples utilize the dried-droplet method that was first introduced by
Hillenkamp and Karas. To facilitate co-crystallization, matrix and samples solutions are
first premixed in a 1:1 ratio. This mixture is then spotted (0.5 µL – 1 µL) onto a MALDI
target plate. Once dried, the sample plate can be inserted into the vacuum system for
analysis. Alternatively, two-layer, three-layer, and sandwich deposition methods are also
available. Many variations of the first two layered techniques exists. Generally, it involves
spotting the matrix, analyte, or matrix-analyte mixture in succession. Sandwich methods
normally involve the sample solution to be “sandwiched” between two layers of matrix
deposits. Overall, matrix molecules must be present in excess for efficient ionization to
occur.

1.5 Introduction of MALDI Mass Spectrometry Imaging
(MALDI MSI)
1.5.1 Theory of MALDI MSI

1.5.1.1 Ionization of Analytes from Intact Tissue Sections

Three ionization techniques used in MSI analysis of intact tissue samples are secondary
ion mass spectrometry (SIMS), desorption electrospray ionization (DESI), and MALDI.
SIMS utilizes an ion beam directed at the sample surface in order to induce the release of
secondary analyte ions for analysis. Although this technique provides images of the
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greatest spatial resolution, it is a hard ionization method and therefore mostly used for
analytes in the lower mass range (<1000 Da) [64]. Alternatively, DESI was introduced by
Dr. Graham Cooks’ research group as a soft ionization method capable of applications
within atmospheric conditions [65]. DESI was developed based on the principles of ESI
and desorption ionization techniques. Ionization occurs as charged droplets are directly
applied onto the sample surface. The charged droplets coat the sample allowing for analyte
extraction. Continuous spray application results in momentum transfer from droplet
collisions and subsequently desorbs analyte ions from the sample surface towards the mass
spectrometer. Development of DESI provides an ionization technique for MSI analysis of
small molecules, lipids, and peptides (< 2000 Da) [66-67].

Development of MALDI MSI by Dr. Richard Caprioli’s research group provided an
alternative soft ionization method for MSI analysis. The molecular specificity and wide
mass range of MALDI-TOF MS has made this technique a powerful tool for imaging intact
biological samples [68-69]. In comparison to the aforementioned ionization methods for
MSI, MALDI provides the greatest applicable mass range making this technique most
suitable for simultaneous MSI analysis of proteins and peptides. MALDI MSI uses fixed
UV laser pulses to extract analyte information from matrix coated tissue sections. This
method of analysis is non-destructive, the ionization process ablates only the matrix layer,
leaving the underlying tissue intact for alternative forms of analysis post imaging. Due to
the complexity of the tissue surface, matrix selection becomes increasingly important to
facilitate the ionization of desired components within the tissue section, while minimizing
undesirable signal detection from the tissue background or matrix. Parameters such as m/z
range, rastor size, laser intensity, shots/ spot, and region of interest (ROI) must be optimized
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for each sample. Once determined, laser pulses ablate each spot as it travels throughout the
designated ROI. These ablations generate analyte ions per spot. The data is then collected,
and processed to represent each pixel within an image of the ROI. A general schematic has
been provided in Figure 1.4.
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Figure 1.4 A schematic of the MALDI MSI workflow. Once the MALDI MSI paramters
are selected, the laser moves along the ROI ablating spot after spot. Information is then
collected for the molecules present within each ablated spot. This information can then be
collectively used to generate a tissue image.
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1.5.1.2 Signal Detection Sensitivity versus Image Spatial Resolution

In MALDI-TOF MSI analysis, both sensitivity and spatial resolution contribute
significantly to the quality of the image generated. Detection sensitivity measures the
instrument’s ability to detect the lowest abundance analyte within a sample, while spatial
resolution describes the ability to resolve two peaks of similar m/z values [70]. The
measurement of sensitivity is directly related to the detection limit of the technique, in
presence of comparable S/N, the greater the detection sensitivity the lower the detection
limit. Therefore, when analyzing proteins and peptides, high levels of sensitivity are
desired in order to overcome issues of lipid abundance within tissue sections. However, the
degree of detection sensitivity acquired is inversely correlated with the level of resolution
attained. The ability to clearly identify two components of a mixture with similar m/z is
extremely beneficial, especially when analyzing biological samples.

To improve detection sensitivity, a larger number of ions must be sent to the detector in a
shorter time frame. This helps to enhance the signal-to-noise (S/N) ratio, and increase the
number of ions detected [36]. Although this may aid to improve sensitivity of detection,
increasing the volume of space for which ions may travel through to the detector,
negatively impacts the resolving power of the instrument. In order to improve the resolving
capabilities, the spatial distribution of the ions must be accounted for. A greater volume of
space contains more ions, but ions of the same m/z with variations in starting energy and
spatial distribution will contribute to differences in arrival times. This in turn decreases
resolution attained. In extreme cases where parameters are greatly optimized for sensitivity,
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the extremely low resolving capabilities will lead to a decrease in S/N as well. Therefore,
in all experiments, a compromise must be made between sensitivity and resolution in order
to find the optimal ratio to provide the necessary information that will answer the question
at hand.

1.5.2 Applications of MALDI MSI

1.5.2.1 Tissue Collection and Storage

Appropriate tissue handling and treatment techniques are crucial in obtaining successful
MALDI MSI results. This involves identifying suitable tissue extraction, sectioning, and
sample preparation techniques. These techniques will differ depending on the sample, and
question under analysis. Therefore, an evaluation is required prior to analysis of every new
sample. Two tissue collection techniques are available for MALDI MSI, fresh frozen and
formalin-fixed paraffin embedded (FFPE) tissue.

With fresh frozen tissue, the greatest issue resides in the ability to homogenously freeze
the tissue section immediately after extraction to maintain integrity and shape. Immediate
freezing helps to minimize protein degradation, which occurs immediately post-mortem
through enzymatic proteolysis. Homogenous freezing can be accomplished through use of
liquid nitrogen, or dry ice. A homogenous freeze minimizes development of ice crystals
within the tissue section, these crystals can then increase chances of tissue fractures upon
sectioning [71]. The tissue can be lightly wrapped with aluminum foil prior to submersion
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in liquid nitrogen, or buried in dry ice to promote a “gentle” freeze application. This can
help to prevent tissue deformities, and the formation of fractures during the freezing
process. Once retrieved, the tissue needs to be stored in – 80 oC to minimize degradation
and chances of ice crystal formation.

Alternatively, recent developments in MALDI MSI allow for the analysis of FFPE tissue.
When tissues are treated with formalin, inter- and intra-molecular crosslinking occurs
between primary amino or thiol groups and arginine, cysteine, tryptophan, lysine, and
histidine residues [72-73]. This crosslinking provides stability and helps to preserves tissue
structure. Therefore, FFPE samples are commonly collected in batches to develop tissue
banks since FFPE tissue can remain stable for decades at room temperature [74]. Although
tissue integrity can be preserved with this method, when analyzing proteins, paraffin is not
compatible with MALDI MSI. Presence of paraffin can result in significant ion suppression
effects, therefore removal must be accomplished through xylene washes prior to analysis
[75]. In addition to paraffin removal, on-tissue digestion is often used to help facilitate
protein and peptide identification among crosslinked proteins [76]. This process helps to
preserve the spatial distribution of resulting peptides for identification.

FFPE tissue retrieval method provides a sample of high stability in comparison to fresh
frozen tissue. However, sample preparatory steps required for successful MALDI MSI
analysis of FFPE tissue is extremely extensive. The paraffin removal process may not
always be 100% successful resulting in ion suppression of lower abundance analytes.
Additionally, the ability to simultaneously detect multiple analytes within tissue samples is
hindered as a result of degradation of lipids within FFPE tissue sections since the only
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molecules preserved are the crosslinked proteins [76]. Therefore, fresh frozen tissue is
often selected in order to preserve the native distribution of analytes within tissue sections,
and to be able to study multiple analytes per sample acquired.

1.5.2.2 Tissue Sectioning and Mounting

Selection of tissue sectioning methods is dependent on the extraction technique used. For
fresh frozen tissue, the tissues are secured onto the holder using water which is flash frozen
with dry ice. As the tissue samples are secured onto the holder, it is important to minimize
embedment of the sample area in water. Embedding the sample in water can result in a
decrease in signal detected as a result of ion suppression effects [77]. Once secured, the
holder can then be placed into the cryotome set to a temperature of -20 to - 25 oC for
sectioning. If the temperature is set too low, chances of tears and tissue fractures occur, but
if the temperature is too high, tissue deformation may occur. Variations in temperature
exists between runs resulting from changes in the temperature and humidity of the
environment. Therefore, if sectioning is performed in an unregulated environment,
temperature settings must be adjusted accordingly. The degree of blade sharpness also
plays a critical role in the quality of sample sections obtained. Ideally, a fresh blade is used
per sample run to minimize variables that could contribute to lack of reproducibility. Tissue
thickness varies between 10 – 35 µm [69]. The optimal tissue thickness is inversely
correlated with the molecular weight of the target analyte in order to facilitate extraction
of larger analytes from the tissue section.
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Once sectioned, tissue is mounted onto indium tin oxide (ITO) coated glass slides. Two
mounting methods are available, flip mounting and thaw mounting. Flip mounting is when
the ITO glass slide is pressed on top the sectioned tissue sample, therefore resulting in the
tissue inversely mounted onto the slide. This mounting method reduces chances of tissue
tearing and deformation, but an increase in noise is detected for these samples. Therefore,
if low abundance analytes are in question, this technique would not be favorable.
Alternatively, the thaw mounting method generates data with a cleaner baseline. Thaw
mounting requires the use of thin brushes to maneuver the tissue section onto the glass
slide. Once desired placement is obtained, the tissue can be thawed onto the ITO glass slide
by placing a finger underneath the slide. Once mounted, the tissue sections must be treated
and analyzed immediately.

For FFPE tissue, sectioning is accomplished using a microtome at room temperature. As
the tissue is sectioned, it is transferred to a water bath of 37 oC, and mounted onto an ITO
coated glass slide. In order to ensure tissue adhesion to the glass surface, presence of water
must be completely removed. This can be accomplished through incubation of the slide at
30 – 37 oC for 1 - 2 minutes. Once mounted, the tissue can be stored at room temperature
for several months prior to analysis.

1.5.2.3 Matrix Application Methodology

MALDI MSI requires the presence of a UV absorbing matrix to be coated on top of the
tissue sections in order to help facilitate the soft ionization process. The matrix deposited
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plays a vital role in the quality of images obtained. Crucial parameters that require
optimization are, uniformity, concentration, and matrix selection. Uniformity of the matrix
layer along the entire tissue section is extremely important for consistent signal detection
in order to obtain an accurate spatial comparison of analytes across the entire ROI. If
uneven application occurs, the concentration of matrix will vary among different areas of
the tissue resulting in differences in the signal intensity detected. Concentration of matrix
used is also extremely important, there is a set window for the optimal matrix concentration
per sample analyzed. If the concentration falls below this range, the analyte to matrix ratio
will be insufficient to maximize signal detection, but if the concentration is greater than
this range, the matrix will act to suppress desired analyte signals. Therefore, optimization
of the matrix concentration is required per sample analyzed. Matrix compatibility with
target analytes must also be considered. Not only does the matrix selection have to be
suitable to the type of analyte under investigation, the solvents used to solubilize the matrix
must also be compatible with the sample. Three methods of matrix application are
available, airbrush, automated sprayer, and sublimation.

Airbrush application is a fast and simple method for matrix deposition for MALDI MSI.
The matrix selected is dissolved in the appropriate solvent and sprayed using an artisan
airbrush onto the tissue section. A major disadvantage of this technique is its poor
reproducibility. Huge variations exist between users since the velocity, duration, and
direction of the spray is controlled manually. Therefore, the quality of the spray can vary
not only between users, but between runs. Although the presence of a solvent facilitates
analyte – matrix interactions which increases extraction potential, a significant concern
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resides in the possibility of spraying too much solvent resulting in delocalization of
analytes on the tissue surface.

Development of automated sprayer systems such as the TM – Sprayer from HTX
Technologies, helped to remove variability in spray parameter. This improved the
reproducibility between runs, and minimized user-to-user variations when depositing
matrix. Automated sprayers provided a platform for users to have full control over desired
spray parameters such as velocity, flow rate, number of passes, spray temperature, and
spray pattern. The robotically controlled nozzle then applies the matrix using the preset
parameters, which allows for the density of matrix applied to be calculated. The ability to
control flow rate helped to facilitate the degree of analyte extraction without significantly
compromising spatial resolution of images acquired. The capabilities of automated
sprayers in regulating parameters to optimize for extraction potential, makes this method
ideal when studying low abundance analytes such as, proteins and peptides.

Among the three techniques, sublimation is the only solvent free application method. With
sublimation, the matrix is placed in the bottom of the reservoir, while the tissue mounted
slide is taped directly above. Ice is added to the reservoir above the slide, and heat is applied
below the matrix reservoir with the entire system under vacuum. The matrix goes directly
from the solid state to the gaseous state. As the matrix particles rise, the ice above cools
the region around the slide resulting in the matrix particles returning to solid state, and
subliming onto the slide. This form of matrix application generates a uniform coating with
a small matrix crystal size. This solvent free technique eradicates the potential of analyte
delocalization, therefore generating images of high spatial resolution. However, the
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absence of solvent also removes the analyte – matrix interaction period, resulting in poor
extraction efficiency. Therefore, sublimation is ideal for generating images of high spatial
resolution for easily extracted or high abundant analytes.
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Figure 1.5 Sublimation was accomplished by adhering the tissue mounted ITO slide onto
the top half of the glass apparatus. This was placed onto the container with the pre-weighed
dry matrix, and the apparatus was then connected to the vacuum pump. Once under
vacuum, the glass apparatus was placed on the heated sand surface.
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1.5.2.4 Sample Rehydration Methodology

As a final step in the sample preparation procedure prior to MALDI MSI analysis,
rehydration is employed to help increase the opportunity for analyte – matrix interactions.
This protocol aims to improve analyte extraction in order to increase detection capabilities.
Rehydration is typically achieved using an acidic solvent within a closed chamber. A filter
paper soaked in the acidic solvent is placed at the base of the chamber, while the tissue
mounted slide is taped onto a metal heat sink attached to the top of the chamber directly
above the solvent. This chamber is sealed and placed in 70 – 85 oC incubator for 3 - 5
minutes. Optimizations for incubation temperature and time vary depending on the matrix
used. This step has been found to improve signal detection for all analytes under
investigation.
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Chapter 2: Alzheimer’s Disease and the Amyloid
Cascade Hypothesis
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2.1 Introduction to Alzheimer’s Disease
Alzheimer’s diseases (AD) is a progressive, and currently irreversible neurodegenerative
disease which affects more than 80% of dementia cases worldwide [1]. This disease can be
categorized into two groups, early-onset AD and late-onset AD. Early–onset is regarded as
the manifestation of AD symptoms before the age of 60. This familial form of AD is caused
by the inheritance of mutated amyloid precursor proteins (APP), and/or presenilin proteins
which represents approximately 1-6% of all AD occurrences [2-5]. Alternatively, numerous
hypotheses for causation factors have been proposed for late-onset AD. However, the
multi-faceted nature of the disease makes it difficult for one theory to encompass all of the
contributing factors for disease development. Biologically, neuronal damage resulting from
AD pathology occur decades prior to the onset of cognitive and behavioural symptoms [68]. During the preclinical stages of the disease, development of amyloid beta (Aß)
oligomers, plaques and tau tangles in the brain continue to facilitate neuronal damage
through disruption of connections eventually resulting in neuronal death [9]. This damage
appears to occur initially in the hippocampus, as a results, the first clinical symptoms
observed tend to be the loss of one’s memory [10-12]. As the disease continues to progress,
the damage eventually spreads throughout the brain, and the symptoms of AD get
progressively worse as it impairs mental, behavioral and functional capabilities of those
affected.

Manifestation of symptoms result in tremendous emotional and financial strains to both the
patient’s families and the health care system. With the incidence rate of AD estimated to
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affect over 1 million Canadians by 2038, AD research has become a prevalent field of study
[13]. Extensive studies in the pathology of AD resulted in constantly changing theories of
causation. Initially, disease manifestation was characterized by high levels of amyloid
plaques, and therefore emphasis was initially placed studying plaque characterization and
development. However, eventually the hypotheses of causation factors shifted to tau
phosphorylation and the Aß peptides as the primary culprits [8]. Challenges in elucidating
AD pathology has resulted as a hindrance to the development of diagnostics and treatments
for the disease. As a result, increased interest has resided in the ability to develop and
explore alternative techniques for the analysis and detection of Aß proteins in hopes to
provide clarity regarding the complex web of factors that contribute to the development of
AD.

2.1.1 Alzheimer’s Disease Pathology

Genetic, environment, behavioural and developmental components all influence the onset
and progression of AD. Therefore, the ability to elucidate definitive cause and effect factors
for this multifactorial disease have been challenging [1]. The earliest hypothesis described
two hallmarks of AD, the accumulation of amyloid resulting in amyloid plaques, and
abnormal hyperphosphorylation of tau leading to neurofibrillary tangles (NFTs) [14-15].
This hypothesis relied on the premise that Aß accumulated in extracellular space resulting
in the development of senile plaques. These plaques then, in turn, led to the formation of
NFTs which both contribute to cell loss, and eventually dementia [16]. However,
continuous research revealed the lack of correlation between disease manifestation and the
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degree of plaque development observed. Additionally, not only was neuronal damage
detected in brain regions free from plaques, significant amyloid plaque formation was
discovered in cognitively normal individuals as well [17-20]. Furthermore, the formation
of amyloid plaques does not occur until much later in AD development, and is therefore
unlikely to be the main driving force of disease progression [21]. Consequently, multiple
theories and factors were hypothesized based on different causation factors of AD as
presented in Figure 2.1. These hypotheses include: the tau hypothesis, inflammation
hypothesis and the amyloid cascade hypothesis (ACH) [22]. Each hypothesis encompasses
multiple factors that cause the onset of AD symptoms. The tau hypothesis postulates that
abnormal increases in hyperphosphorylated tau proteins found in AD patients result in the
loss of normal tau functions leading to neuronal dysfunction [23-27]. The inflammation
hypothesis focuses upon the inflammation of the central nervous system which leads to
oxidative stress followed by neuronal death [28-29]. The ACH indicates that Aß
accumulation is the primary initiator that triggers a cascade of events resulting in neuronal
death and dementia exhibited in AD patients [7].
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Figure 2.1 A simplified schematic demonstrating factors that influence AD development
and progression modified from Anand et al. [1]. The factors are found to be largely
interconnected in causation and effect. All the individual events lead to neuronal death or
dysfunction, and the eventual onset of dementia.
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2.1.2 Amyloid Cascade Hypothesis (ACH)

Among the proposed hypotheses for AD development and progression, ACH retains focus
due to the correlations observed regarding neuronal toxicity, and the presence of soluble
Aß oligomers. The presence of Aß oligomers were found to induce neuronal damage, and
induce memory loss with or without plaque formation [30-31]. In the preliminary phase of
ACH development, researchers believed the overproduction, or a decrease in clearance
efficiency of Aß peptides resulted in an accumulation of Aß1-40 and Aß1-42 [8]. As the
concentration of Aß peptides increases, peptide aggregation occurs which induces a
multifaceted neurotoxic cascade of events. This includes the hyperphosphorylation of tau
proteins, neuronal loss, cerebrovascular damage, and microglia activation [30].

Aß production results from proteolytic processing of the amyloid precursor protein (APP).
This occurs either through the amyloidogenic, or non-amyloidogenic pathways. In normal
conditions, the non-amyloidogenic pathway uses α-secretases which cleaves APP within
the Aß domain (between Lys16 and Leu17) resulting in the release of sAPPα. However,
under pathological conditions, the amyloidogenic pathway uses ß-secretases. The ß
cleavages site is located at the beginning of the Aß domain, therefore lceavage through ßsecretase generates sAPPß. The following γ-secretase cleavage then releases Aß peptides
[8, 14, 32]. Continuous Aß production along with poor Aß removal induces the damages
which eventually results in neuronal death. The development of the ACH throughout the
years has made this theory the most well defined, and greatly studied concept for AD
pathology.
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2.2 Amyloid Beta
2.2.1 Physical Properties

Aß plays an important role in biological processes such as signaling, neuronal development
and intracellular transport [33]. The amino acid sequence of these peptides contains
approximately 50% hydrophobic residues with the majority of these residues concentrated
on the latter half of the sequence (Figue 2.2). The hydrophobic stretches in the middle and
C-terminus of Aß1-42 are the driving forces of the aggregation process [34]. The
hydrophobic composition of Aß creates challenges in sample handling under research
conditions. Therefore, strong emphasis must be placed on ensuring sample integrity prior
to additional analysis on biological effects within an experimental system.

Aß1-40

DAEFRHDSGY EVHHQKLVFF AEPVGSNKGA IIGLMVGGVV

Aß1-42

DAEFRHDSGY EVHHQKLVFF AEPVGSNKGA IIGLMVGGVV IA

Figure 2.2 Amino acid sequence of pathogenic Aß peptides 1-40 and 1-42 have been
provided. The peptide contains approximately 50% hydrophobic residues (shown in red).
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2.2.2 Aß Assemblies

Monomeric Aß undergo aggregation which results in the formation of low molecular
weight oligomers followed by higher molecular weight aggregates. These aggregates
develop into spherical oligomers comprised of 12 to 24 monomers. The spherical structure
then elongate into protofibrils, and finally insoluble fibrils as seen in Figure 2.3 [35]. These
variations in Aß assemblies then come together to form amyloid plaques. The soluble Aß
oligomers possess a heterogeneous size distribution in vivo due to the monomers propensity
for spontaneous aggregation [33]. With the help of circular dichroism (CD), infrared
spectroscopy and hydrogen/deuterium exchange (HDX), Aß oligomers were found to
possess significant ß-sheet secondary structures [36]. The transient nature of Aß oligomers
make it extremely difficult to produce in vitro samples of homogenous oligomer
composition, making the structural characteristic of Aß oligomers more challenging to
identify [37]. The staple characteristic of these oligomers is the apparent ß-sheet structure
arranged in parallel and antiparallel fashion [38]. Initially, development of spherical
oligomeric aggregates was thought to be required prior to the formation of long protofibrils
leading to the formation of fibrils. However, studies indicated protofibril development can
potentially occur directly from the monomeric state as well. Uncertainties in Aß structure,
and the developmental pathways elicit continuous developments in analytical methods for
the identification and analysis of this protein.

Unlike the dynamic oligomeric form of Aß, the static structure of the Aß fibrils has been
well characterized. Aß1-40 and Aß1-42 fibrils consist of ß-strands which run perpendicular to
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the fibril axis [39]. The ß-strands run antiparallel in a ß-hairpin motif, where the first and
second ß-strands are connected by a short loop [40-43]. The first ß-strand begins after the
initial disordered stretch of amino acid residues at the N-terminus (approximately residues
1-14). This strand is followed by a turn which leads into the second ß-strand [44-45].
Hydrogen bonding between these strands results in parallel stacking of the protomers
forming protofibrils. The protofibrils developed can then twist together to become mature,
stable fibrils. The ß-sheet structure of amyloid fibrils act efficiently in burying the
hydrophobic side chains within. Complete elucidation of the Aß aggregation pathway for
the development of toxic oligomers, and stable fibrils may help to reveal underlying
mechanisms of Aß related neurodegenerative diseases.
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Figure 2.3 Different stages of Aß aggregation has been presented in the currently
understood aggregation pathway. Aß monomers aggregate to form a heterogeneous
composition of soluble oligomers. These oligomers elongate to form the transitional
protofibril structure prior to the development of mature, insoluble fibrils. However,
supporting evidence indicate the monomeric form of Aß can potentially aggregate directly
into protofibril formation as well.

80

2.2.3 Biological Functions & Neurotoxicity of Amyloid Beta

The complexity of AD resulting from the pathogenic interactions between genetics,
epigenetics, and the environment makes it challenging to develop therapeutic interventions
for AD management. Novel therapeutics are focused on facilitating amyloid oligomer
reduction by inhibition of Aß production, or by improving the efficiency of Aß degradation
through over-expression of Aß degradation enzymes [33]. Beta (ß)- and Gamma (γ)secretase inhibitors, or modulators have been introduced as a means to prevent the
production of Aß by minimizing the cleavage of APP through the amyloidogenic pathway.
The hope was that this process would defer APP cleavage towards the non-amyloidogenic
pathway using α-secretase [46]. Unfortunately, these interventions are still undergoing
clinical trials, therefore there are a limited number of approved drug treatments currently
available for AD management [33].

Increased understanding of the mechanisms for Aß toxicity is required to further the
development of therapeutic treatments for AD. However, due to the complexity of oligomer
formation, there has been several proposed mechanisms for Aß toxicity [47]. Aß toxicity
has been linked to the disruption of receptors, including the induction of the nerve growth
factor (NGF) receptor mediated neurodegeneration and cell death [47-49]. Aß was also
found to bind to membrane proteins such as insulin receptors. Similarities in structure result
in Aß competing with insulin for insulin degrading enzymes resulting in the impairment of
glucose metabolism observed in AD [50-51]. Since the plasma membrane regulates the
exchange of materials between cells and the environment, the structural integrity of these
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membranes is crucial for cellular viability. xtracellular aggregation of Aß deposits within
the hippocampus, amygdala, entorhinal cortex and basal forebrain contribute towards the
deteriorating memory, learning and emotional behaviours found in patients suffering from
AD [33, 59].

In attempts to isolate therapeutic interventions, the development of various techniques for
in vitro Aß analysis have been developed. Researchers aimed to probe the physical and
chemical properties of these toxic proteins to identify the origins of its toxicity within
biological systems. These techniques include: nuclear magnetic resonance (NMR), X-ray
diffraction crystallography, as well as spectroscopy and microscopy based methods. Both
NMR and X-ray diffraction crystallography are able to provide 3D structures of
amyloidogenic peptides and proteins. NMR is able to monitor protein folding, including
the secondary structures, along with the interactions among different regions of the protein
[60-62]. Through NMR analysis, amino acid residues 1-14 were found to be unstructured,
polar, water soluble residues while segment 15-36 form α-helical structures [63]. Helical
sections of the protein convert to coils upon the loss of a proton for two acidic amino acid
residues. This conversion was found to precede the aggregation of Aß1-40 [63]. In
comparing the physical structure of Aß1-40 and Aß1-42, residues 31-34 and 38-41 in Aß1-42
was found to form ß-hairpin structures resulting in a reduction of the flexibility at the Cterminal [64]. This was speculated to be a factor of the peptides greater propensity for
aggregation in comparison to Aß1-40. Currently, gel electrophoresis is commonly used for
identification of Aß aggregation in biological samples [65]. This technique relies on the
ability of SDS to bind to proteins of interest, however this binding can also compromise
the structural integrity of desired aggregates [66]. Issues regarding low sample throughput,
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limitations in resolution, as well as gel smearing can reduce the effectiveness of this
technique. Alternatively, atomic force microscopy (AFM), surface plasmon resonance
(SPR), absorbance, and fluorescence spectroscopy have been used to study Aß composition
with some success [67-68]. Each technique possesses its own set of limitations. AFM is
most suitable for studying large, stable amyloid fibrils, while SPR is generally used to
investigate the interaction of Aß aggregates. Both absorbance and fluorescence
spectroscopy present restrictions in the ability to differentiate between aggregates of
differing sizes.
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2.3 Amyloid Beta Imaging
Techniques for Aß imaging within intact tissue sections have evolved greatly in the past
two decades in response to the increasing demands within both research and commercial
fields. Localization of Aß proteins within intact brain sections can help to elucidate AD
progression and associate effects patients experience. Traditionally, histological stains
using Congo Red or Thioflavins on formalin-fixed paraffin embedded (FFPE) tissue can
be used for the identification of amyloid in tissue samples [69-70]. Alternatively,
monoclonal mouse antibodies can be used to tag, and locate pre-amyloid and amyloid
deposits with immunohistochemistry (IHC). However, issues reside with background
staining caused by serum cross reactivity, or poor antibody specificity [71-72].

Through the introduction of mass spectrometry imaging (MSI), comprehensive analysis of
the spatial distribution for molecular components eliminates the need for chemical staining,
or antibody labelling. Over the last 10 years, continuous developments in matrix-assisted
laser desorption/ionization mass spectrometry imaging (MALDI MSI) has been beneficial
for the spatial profiling of amyloid plaques. However, currently MALDI MSI analysis of
Aß has been limited to the detection of fibrillary Aß and amyloid plaques, both of which
possess very stable, sedentary structures of considerable size [73-76]. The ability to
identify soluble oligomeric forms of Aß through MALDI MSI is still required. Chapter 3
aims to present MALDI MS as a method of analysis for soluble Aß oligomeric samples.
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2.4 Overview of Thesis
The main goal of this thesis is to improve methods for protein and peptide detection in
MALDI MSI. A picture says a thousand words, we hope to apply this technique for the
analysis of proteins and peptides in order to provide additional insight on disease
development and progression. In the past few years, MALDI MSI has become a prominent
tool in the study of intact biological samples. This method provides a new platform to not
only identify and characterize target molecules within tissue samples, but also to
investigate the significance of the distribution for these compounds. This thesis focuses on
the analysis of amyloid beta (Aß) proteins which are found to be strongly correlated with
Alzheimer’s disease (AD) progression. The developments accomplished to improve
detection sensitivity of MALDI MSI in the analysis of proteins and peptides will be able
to provide a wealth of information to propel our understanding of disease onset and
pathology, as well as to further the understanding of drug transport in order to aid in drug
design.

The thesis begins with an overview of MALDI MS and the technical elements of this
technique, followed by details regarding the application of MALDI MSI. Difficulties of Aß
analysis, and the significance of this protein in regards to AD are outlined. Chapter 3
focuses on the development of a sample preparation protocol in the MALDI MSI detection
for a small peptide. The ability of MALDI MSI in the detection and analysis of lipids and
metabolites have been well reported in the last decade of MALDI MSI development.
However, the capabilities of proteins and peptides detection using this technique are still
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fairly limited. Therefore, we begin our study of MALDI MSI by investigating a dipeptide,
ZP1609. Optimization and modifications to sample preparation protocols were employed
in order to detect ZP1609 within intact mouse brain sections. In chapter 4, the focus then
shifts to the study of the Aß peptide. Variations in sample preparation techniques, and the
ability for MALDI MS detection of different Aß fragments were reported. MALDI MSI
developments outlined in chapter 3 were then applied to the analysis of Aß in chapter 5.
Issues of poor signal resolution, and detection sensitivity were encountered. Solid-phase
extraction using magnetic beads was attempted to enhance signal detection capabilities of
MALDI MSI.
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Chapter 3: Matrix-Assisted Laser Desorption/Ionization
Mass Spectrometry Imaging of Intraperitoneally
Injected Danegaptide (ZP1609) for Treatment of
Stroke-Reperfusion Injury in Mice
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3.1 Introduction
3.1.1 MALDI MSI Analysis of Small Peptides

Visualization of biological systems provide a platform to unravel and understand the
complexities of cells, disease pathology and drug pathways. The molecular specificity of
mass spectrometry imaging (MSI) and the “soft” ionization source, has made matrixassisted laser desorption/ionization (MALDI) MSI a powerful, emerging tool for imaging
intact biological tissue samples [1-3]. The specificity and sensitivity mass spectrometry
provides allows it to be used as a new technology for directly mapping and imaging intact
biological tissue sections [4-6]. Current imaging techniques for biological specimens have
contributed greatly in the study of biological systems, and the practice of medicine, but a
common limitation resides in the inability for untargeted monitoring of multiple analytes
simultaneously without introduction of labels or structural modifications to the system [7].
MALDI MSI can overcome this limitation by monitoring thousands of molecules within
one experiment in order to study the spatial arrangement within tissue sections [8-9]. This
technique is capable of localizing proteins, peptides, lipids, metabolites and small
molecules in situ [10-11]. The data acquired can help shape our understanding of biological
functions and diseases in order to improve current methods of treatment and prevention.
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3.1.2 Biological Significance of Danegaptide (ZP1609)

It is estimated that over 600,000 Canadians will be suffering from the effects of stroke by
the year 2038 [12]. Stroke occurs when there is restricted blood flow to the brain resulting
in loss of oxygen and neuronal cell death [13-14]. These infarctions result in debilitating
effects, such as mobility limitations, chronic pain, vision problems, and excessive fatigue
which impact the lives of not only the patients, but also puts extensive strain on the
caregivers [15]. Antiarrhythmic drugs like rotigaptide (ZP123) were originally described
to protect against cardiac ischemia-reperfusion injury as it exhibited protection in ischemic
conditions [16-19]. Further development of ZP123 produced ZP1609 which exhibited
similar effects as its parent compound, but it has the additional advantage of improved oral
bioavailability making it a stronger candidate clinically [20-22]. When assessing the
protective properties of ZP1609 in pre-clinical models of stroke-reperfusion injury, results
demonstrated a decrease in infarct size when ZP1609 was administered prior to the
reperfusion phase following ischemic conditions [14, 21, 23-24]. However, a current
limitation to using ZP1609 as a neuroprotective agent for stroke, is a clear understanding
on the ability of the dipeptide to target the brain itself. Blood brain barrier (BBB)
permeability is essential for potential drug candidates in drug discovery programs. The
BBB is designed to protect the central nervous system from toxins and pathogens, but this
characteristic also acts to restrict the delivery of drugs to the brain [25-27]. Visualization
of drug distribution can be achieved through radiolabeling drug derivatives, but this method
is susceptible to false positives and is expensive to execute [28]. More importantly, the
labels can potentially change the property of a small drug molecule. MALDI MSI provides
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a label-free method capable of visualizing distribution of drug molecules within tissue
sections. The ability to visualize BBB permeability of ZP1609 will give a better
understanding of drug transport, toxicity, and help to predict potential off-target effects to
advance development. This method is effective, yet requires experimental optimization,
such as matrix selection and tissue washing to successfully detect the analytes of interest.

ZP1609 has a monoisotopic mass of 291.12 Da, consisting of a benzamide group attached
to amino acid residues proline and glycine (Figure 3.1). Investigation of the BBB
permeability of ZP1609 using MALDI MSI can help advance our understanding of the
neuroprotective properties of this compound against ischemic stroke. With MALDI MS,
the matrix helps to transfer the laser energy for the “soft” ionization of analyte molecules
and facilitate their detection, but even so, fragmentation still occurs especially for small
peptides like ZP1609. Ideally, MALDI MS is capable of the direct analysis of ZP1609 from
the complex background of biological tissues while simultaneously searching for possible
fragments and adducts of ZP1609. Within this work, we demonstrate MALDI MSI
capabilities in the direct detection of an intraperitoneally (IP) injected small peptide,
ZP1609 within intact tissue sections as well as provide visual confirmation of the
dipeptide’s successful penetration of the BBB.

95

Figure 3.1 ZP1609 dipeptide has a monoisotopic mass of 291.12 Da. This dipeptide
consists of a benzamide group attached to proline and glycine amino acid residues.
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3.2 Experimental
3.2.1 Apparatus

All MALDI MS sample analyses were performed on a Sciex TOF TOF 5800 MALDI mass
spectrometer equipped with a 1 kHz OptiBeamTM On-Axis Nd:YAG laser system (Ontario,
Canada). The TOF TOF Series Explorer and Data Explorer were used for data acquisition
and processing respectively. The Sciex TOF TOF Imaging software was used for region
selection and image data collection. All MALDI MSI data was processed and analyzed
using MathWorks MATLAB MSiReader software.

Matrix sublimation was accomplished using a glass sublimator built in-house. Spray matrix
application was applied using HTX Technologies automated TM Sprayer system (Chapel
Hill, NC). CryoStar NX50 from ThermoFisher Scientific (Ontario, Canada) was used for
all tissue slicing. Syringes and Needles used for sample preparation were purchased from
Dyna Medical (Ontario, Canada), and Becton-Dickinson & Co (Franklin Lakes, NJ)
respectively. Rehydration chambers were created with Fisherbrand Petri Dishes from
Fisher Scientific (Ontario, Canada) and rehydration was achieved using a Robbins
Scientific Micro Hybridization Incubator Model 2000 (San Diego, CA). Deionized water
used throughout these experiments were obtained from a Millipore Milli-Q A10 Water
Purification System (Bedford, MA).
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3.2.2 Samples and Reagents

All ZP1609 standards were supplied by Dr. Christian Naus from the University of British
Columbia. Reagent grade acetonitrile (ACN), ammonium hydroxide, ethanol, and
methanol were purchased from Caledon (Ontario, Canada). HPLC grade trifluoroacetic
acid (TFA) was purchased from Fischer Scientific Ltd. (Hampton, NH). 2, 5 –
dihydroxybenzoic acid (DHB), sinapinic acid (SA), chloroform, ammonium citrate dibasic,
and acetic acid were purchased from Sigma Aldrich (St. Louis, MO). Phosphoric acid was
obtained from EM Science (Darmstadt, Germany), and trifluoroacetic acid (TFA) was
purchased from Fischer Scientific (Ottawa, ON, Canada).

3.2.3 Treatment Conditions for Tissue Samples

All procedures were approved by the Animal Care Committee of the University of British
Columbia. Wildtype C57Bl/6 mice from the Jackson laboratory (Maine, USA) aged 3-4
months were used. Transient Middle Cerebral Artery Occlusion (tMCAO) was performed
according to the protocols of Lee et al. and Maniskas et al. [29-30]. Briefly, the mice were
anesthetized with sodium pentobarbital (65 mg/kg IP) and given an opiate, buprenorphine
(0.1 mg/kg). A local analgesic, bupivacaine (0.1 mL at 0.25%), was administered at the
incision site prior to surgery. The mouse’s head was immobilized in a stereotaxic frame to
allow exposure and blockage of the middle cerebral artery. The mouse brain was subjected
to anoxic conditions for 1 hour followed by reperfusion of the blood supply. Following
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injections of treatment compounds at designated time intervals, the mice were anesthetized
using a lethal dose of sodium pentobarbital (120 mg/kg IP) and transcardially perfused with
phosphate-buffered saline (PBS). The brains were removed and frozen at - 80 oC.

The treatment paradigm was as follows: 1) Sham – saline brains; saline was IP injected and
brains were removed 1 hour after injection. 2) Sham – ZP1609 brains; ZP1609 was IP
injected and brains were removed 1 hour after injection. 3) Stroke – saline brains; tMCAO
with reperfusion after 1 hour; saline was injected 10 minutes before reperfusion IP and
brains were removed 1 hour later. 4) Stroke – ZP1609 brains; tMCAO subjected brains
with reperfusion after 1 hour and ZP1609 was IP injected 10 minutes before reperfusion.
Brains were removed 1 hour later. 5) Stroke – saline brains; tMCAO subjected brains with
12 hours delayed extraction brains; saline was injected 10 minutes before reperfusion by
IV, followed by IP injections every consecutive hour for 3 hour. The brains were removed
after 12 hours. 6) Stroke – ZP1609 brains; tMCAO subjected brains with 12 hours delayed
extraction; ZP1609 IV injected 10 minutes before reperfusion followed by IP injections
every consecutive hour for 3 hours. Brains were removed after 12 hours.

3.2.4 Tissue Preparation for MALDI MSI Analysis

Tissue samples were mounted onto the tissue holder of the cryostat with water, and coronal
sections were obtained to 14 μm thicknesses at - 25 oC. Each tissue section was
approximately 5.5 – 9 mm by 7 – 9 mm in size. Once sliced, the sections were thaw
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mounted onto indium tin oxide (ITO) coated glass slides and placed in a desiccator for 10
minutes.

A six step wash first using, 70% ethanol, and 100% ethanol was employed. This was
followed by a mixture of 60% ethanol, 30% chloroform, and 10% acetic acid. Finally,
another 100% ethanol, water, and 100% ethanol was used. The wash steps fix the tissue
sections, as well as removes unwanted contaminants, salts and lipids. Upon tissue
acidification, the water wash was replaced with 0.2% TFA. The tissue was incubated in this
solvent at room temperature for 2.5 minutes.

3.2.5 MALDI MSI Analysis

DHB matrix was prepared to 20 µg/µL in 20% EtOH, 15% 100 mM ammonium citrate,
and 1% phosphoric acid. When sublimated, 210 mg of DHB was used and sublimated at a
temperature of 130 OC for a duration of 4 minutes. DHB was also applied onto sample
sections using the automated TM sprayer from HTX Technologies (Chapel Hill, NC).
Complete sample coverage was obtained using 8 passes at a velocity of 1200 mm/min, and
a flow rate of 0.05 mL/min. A final matrix density of 3.33 x 10-2 mg/mm2 was achieved. A
final rehydration step was performed using a 5% acetic acid solution. The sample slide was
placed in the rehydration chamber at 70 oC for 3.5 minutes.

The MALDI MS sample analyzed in the positive ion, reflectron mode. A total sum of 600
shots/spot, and 30 shots/spot for spectral and imaging data acquisition respectively with a
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1 kHz OptiBeam On-Axis Nd:YAG laser system. The open source MSiReader software
was used for imaging data manipulations and analysis.

3.3 Results and Discussion
3.3.1 Identification of Danegaptide Peaks

We first determined the sensitivity of MALDI MS for the detection of intact dipeptide,
fragments, and adducts. Of the common matrices, 2,5-dihydroxybenzoic acid (DHB) has
been found to be more susceptible to in-source decay, therefore making detection of
ZP1609 fragments, along with corresponding salts and adduct formations possible [31-32].
Images for the intact peptide, along with confirmed fragments, salt ions, and adducts help
to validate the data in order to show MALDI MSI capabilities in targeting analysis of small
peptides in complex biological samples. Identification of ZP1609 standards was achieved
using MALDI MS peaks of fragment ions, salt ions, and adducts listed in Table 3.1. As a
result of the presence of salts within the complex samples, Na+ and K+ ions were commonly
detected within the sample. Cleavage of glycine and proline also generated detectable
peaks within the targeted m/z range of 100 – 550.
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Table 3.1 Peaks identified through MALDI MS analysis of standard ZP1609 samples were
recorded. These peaks include dipeptide fragmentation as well as any salt ions, and adducts
formations detected within the m/z range of 100 – 550.

Description

Ion m/z

[Glycine – H + Na +K]+
[Proline – H + 2Na]+
[M – C2H4NO + 2H]+
[M – CO2 + H3O]+
[M – CO2 + K]+
[M+H]+
[M + 2H]+

135.96
160.03
235.11
266.14
286.14
292.13
293.14

[M + Na]+
[M + K]+

314.13
330.13
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3.3.2 Effects of Variation in Matrix Selection

The sensitivity of detection for the target m/z range of 100 – 550 for standard matrices
sinapinic acid (SA), and 2,5 – dihydroxybenzoic acid (DHB) was then assessed for MALDI
MSI within intact mouse brain tissue sections. Although α-cyano-4-hydroxycinnamic acid
(CHCA) has been shown to be effective for low mass peptide analysis, CHCA generates
an abundance of matrix background signals of high signal intensity within the 100 – 500
range and thus CHCA peak intensities suppressed the ZP1609 signal. Although SA is
normally used for analysis of small proteins, both DHB and SA matrices have been found
to be highly effective for MALDI MSI analysis, therefore both matrices were tested for
ZP1609 analysis [33-34]. For matrix comparisons, brain tissue samples from the
experimental group with IP injected ZP1609 were coated with either SA or DHB and
profiling data were collected (Figure 3.2). Among these two matrices, DHB was found to
provide the greatest detection sensitivity of the target analytes with minimal interference
from background. The majority of peaks observed with SA resulted from the matrix itself,
while use of DHB allowed for detection of [M + H]+ peaks.
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Figure 3.2 ZP1609 signal detection capabilities of SA (A), and DHB (B) were compared
to select the most suitable matrix for image application. SA generated little to no analyte
signals in comparison to DHB. This was further proven when data was collected with focus
on the targeted m/z region 280 – 300. The [M + H]+ peak at m/z 292.13 was identified when
DHB was used for analysis.
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3.3.3 Effects of Tissue Washing in Signal Detection

Following determination of matrix and target m/z for analysis, optimization of MALDI
imaging parameters was explored. Standard sample preparation protocols for MALDI MSI
of proteins and peptides for fresh frozen tissue sections include, tissue extraction,
mounting, fixation, wash, matrix application and rehydration [7]. Salts and lipids cause a
signal suppression effect on the targeted proteins and peptides so additional fixation and
washing steps are required for the detection of target proteins and peptides in MALDI MSI
[35-36]. As a result of these sample preparation procedures, compromises in signal and
spatial resolution, as well as delocalization of target analytes are often observed when
imaging proteins and peptides. Changes in these imaging parameters together contribute to
a reduction in image quality when compared with MALDI MSI of lipids. Even though
current sample preparation protocols commonly used in our research group have been
devised for lipid imaging generating high resolution lipid images, there is still room for
improvement when imaging proteins and peptides which typically requires salt and lipid
removal by tissue washing. As such, in this study we assess and optimize sample
preparation methods for IP injected dipeptides using ZP1609 as the analyte of interest. With
peptides of such a low molecular weight (MW) range, tissue washing procedures must be
monitored closely to determine whether sample loss poses as a critical factor for signal
detection. Wash protocols vary greatly depending on the target analytes that are being
investigated. The six step wash protocol was adopted from the Caprioli research group and
was modified to maximize efficiency for our target analyte [36]. The six washes were
intended to first fix the tissue with ethanol to prevent further degradation, followed by
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removal of lipids and salts. The ethanol, chloroform and acetic acid mixture serves as a
means of lipid removal while a water wash removes excess salts from the tissue section.
Each step of the wash protocol helps to remove the endogenous contaminants that may
hinder desorption and ionization of peptides. Effects of peptide detection following the
wash protocol was clearly displayed in Figure 3.3. These wash conditions show significant
enhancements in detection sensitivity and the signal-to-noise ratio when investigating the
[M + H]+ peak at 292.13.

3.3.4 Effects of Variation in Methods of Matrix Application

The most widely used forms of matrix application are sublimation or automated spraying.
Sublimation provides a means of matrix application without involvement of solvents thus
minimizing the chances of additional adduct formation, as well as eradicating the
possibility of delocalization producing an image of high spatial resolution [37]. The
compromise that comes with sublimation is the reduction in analyte extraction capabilities
resulting from the lack of solvent interactions to aid in the co-mixing of target analytes and
matrix. When the two matrix application methods were compared for the detection of the
small peptide ZP1609, it was clear the automated sprayer provided greater detection
sensitivity as well as better signal-to-noise providing an image of greater structural details
(Figure 3.4). Although the rehydration step aids in analyte extraction, when analyzing
small, low abundance peptides, sublimation still appears to be inferior to matrix sprayers
in analyte extraction efficiency. This deficiency resulted in images of poor signal and
spatial resolution in comparison to the sprayer.
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Figure 3.3 An abundant amount of lipids and salts were present on the surface of the tissue
section resulting in signal suppression effects of the [M + H]+ peak (m/z 292.13) for ZP1609
(A). Upon removal of the excess salts and lipids through the wash protocol, detection of
the target analyte was achieved (B).
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Figure 3.4 The [M + H]+ peak of ZP1609 at m/z 292.13 was used to assess extraction
capabilities for small MW, low abundance peptides. Sublimation was used as a dry matrix
application technique (A), this was compared to a wet application technique through use
of an automated sprayer (B). The lack of solvent to facilitate extraction of target analytes
resulted in poor signal-to-noise ratio hence compromising detection sensitivity and spatial
resolution of the images obtained.
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3.3.5 Acidification Effects on Signal Detection Sensitivity

Through optimization of sample preparation protocols, we were able to detect ZP1609, but
there was room for improvement in the images obtained. Therefore, increased acidification
during the wash protocol was tested for its ability to enhance image resolution for low MW
peptides. During the wash protocol, TFA was added to the water wash for excess salt
removal. The tissue was washed for an extended period of 2.5 minutes in this TFA solution
to allow for sufficient acidification of the tissue sample. This acidification process coupled
with rehydration after matrix application using a 5% acetic acid solution resulted in greater
signal detection capabilities as well as an image of greater spatial resolution (Figure 3.5).
The maximum signal intensities detected per image have been displayed for direct
comparison.
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Figure 3.5 The [M + H]+ peak of ZP1609 at m/z 292.13 was used to assess the effects of
extended acidification in extraction capabilities. To facilitate acidification, the water wash
used for salt removal (A) was replaced with 0.2% TFA solution (B). Sensitivity of detection
was improved when the tissue washing protocol was modified to include an extended
acidification step allowing for higher signal intensity as well as identification of greater
structural differentiation within tissue when target m/z values were assessed.
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3.3.6 MALDI MSI Analysis of Intraperitoneally Injected ZP1609

Using the above mentioned sample preparations methods, different experimentally treated
mice brain samples were compared. Mice underwent four different surgical conditions
(sham-saline, sham-ZP1609, stroke-saline, and stroke-ZP1609) in order to determine the
efficiency of ZP1609 in penetrating the BBB to reach the brain parenchyma. Several
fragment ions were targeted in order to validate the MALDI MSI data obtained was a result
of the presence of ZP1609, and not by-products of the protocols. These fragment ions were
previously determined when standards of ZP1609 were analyzed. Targeted m/z values
were, 160.03, 266.14, 314.13, and 330.13 and these peaks correlate directly with, [Proline
– H + 2Na]+, [M – COOH + H2O]+, [M + Na]+, and [M + K]+ respectively (Figure 3.6).
When analysing saline injected tissue in comparison to the ZP1609 injected tissue, it was
clear that the targeted peaks were detected with greater signal intensity. The most intense
signals were detected from tMCAO subjected mice brains that underwent ZP1609 peptide
injection in ischemic conditions followed by reperfusion. ZP1609 was found to exhibit
similar protective behaviours as its parent ZP123 by countering the reduction of
conductance efficiency under ischemic conditions. Therefore, a greater presence of
ZP1609 was expected when treatment groups were subjected to tMCAO conditions. These
speculations were supported by the data presented in Figure 3.6. When comparing ZP1609
injected vs. tMCAO & ZP1609 injected tissue sections, a clear increase in signal intensity
was observed.
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Figure 3.6 MALDI MSI was able to detect low concentrations of IP injected ZP1609.
Analysis of the fragment and salt ions, help reinforce the data suggesting the dipeptide’s
successful penetration of the blood brain barrier.
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With the optimized protocol and added tissue acidification procedure, tissue samples from
different treatment groups were analyzed and found MALDI MSI signal detection was
sensitive enough to differentiate between treatment groups. Two negative controls were
provided, one with saline IP injected in normal conditions, while the other was injected
with saline in ischemic conditions followed by reperfusion. The sample preparation
protocol was then tested using samples from treatment groups which followed the protocols
of current preclinical trials. This protocol differed in multiple ZP1609 injections were
administered before reperfusion as well as after in 1 hour intervals. The tissue extraction
was then delayed 12 hours following reperfusion in order to provide ample time so ZP1609
can be efficiently transported across the BBB. If ZP1609 is effective in penetrating the
BBB, then continuous drug delivery should permeate the brain allowing greater signal
intensity to be observed and in turn provide a greater signal-to-noise ratio. The images
generated from this sample group possessed greater spatial resolution and signal intensity
(Figure 3.7).
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Figure 3.7 Saline and ZP1609 was administered pre and post reperfusion in one hour
intervals for the control and treatment groups respectively. Analysis of target ZP1609
fragment and salt ions generated images of higher spatial resolution and signal intensity.
The extended incubation period provided additional time for the dipeptide to permeate the
brain tissues resulting in a greater signal detection for each fragment analyzed.
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3.4 Conclusion
MALDI MSI shows the benefits of tissue acidification to enhance detection sensitivity and
overall image resolution. Analysis of ZP1609 using MALDI MSI shows the specificity of
sample preparation parameters required to obtain successful images of small peptides
within tissue sections. These parameters require optimization in order to cater to analytes
under investigation. Through manipulations of the preparation protocol, we were able to
obtain data that uncovers the capabilities of ZP1609 in successful penetration of the BBB.
MALDI MSI has shown to be a useful technique for drug detection in intact tissue sections.
This demonstrates the ability of the technique to provide important information regarding
drug transport to help further develop ZP1609 as a means of pharmaceutical intervention
in minimizing effects of stroke-reperfusion injury.
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Chapter 4: Detection of Amyloid Beta Oligomeric
Composition Using Matrix-Assisted Laser
Desorption/Ionization Mass Spectrometry (MALDI MS)
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4.1 Introduction
Alzheimer’s disease (AD) is now considered the most common cause of dementia, and the
6th leading cause of death in the United States with over 5 million North Americans
suffering from this disease [1]. The adverse neuropsychiatric and behavioral symptoms
patients suffer from pose as a significant strain on our health care system, and give rise to
socioeconomic issues. Hallmarks of the disease include extracellular plaques characterized
by the accumulation of protein-containing deposits primarily consisting of amyloid beta
(Aß) peptides and intracellular neurofibrillary tangles caused by aberrant phosphorylation
of tau [2-4]. Previous work found these large fibrillary Aß structures within neuritic plaques
killed cultured neurons [5]. This and other evidence led to the amyloid cascade hypothesis
(ACH) which originally postulated that these insoluble fibrillary aggregates were the
primary cause of neurodegeneration in AD patients [6]. Although extensive research has
targeted these plaques, poor correlation between neurological deficits and plaque
accumulation have been observed in AD patients [7-8].

Recent studies have shifted focus to examine the onset of Aß aggregation from the
monomeric peptides to the soluble form of Aß multimeric complexes, and found evidence
linking the accumulation of the Aß oligomers to the progression and severity of AD, in
particular, with long term hippocampal, age-onset memory failures [2-3, 9-12]. Due to
these recent findings, modifications to the amyloid cascade hypothesis have been made to
target the role of soluble Aß oligomers in disease progression [13-15]. In healthy
individuals, Aß peptides are degraded within or cleared from the brain [16-17]. Reduction
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in the degradation or clearance efficiency results in accumulation of the soluble oligomers
that correlate with disease onset and progression. Understanding the mechanisms and
effects of Aß oligomerization in the brain is therefore critical to the development of novel
therapeutics for AD. A common experimental approach is the in vitro toxicity essay of Aß
oligomers on neuron cell cultures, where cellular viability is quantified to determine the
effects of various forms of Aß and/or potential therapeutics [18-22]. The Aß samples for
the in vitro experiments are typically obtained from commercial sources. Numerous
protocols have been reported for in vitro oligomeric Aß1-42 preparations with the largest
variation residing in the monomerization and oligomerization solutions used [23-26].
Surprisingly, to our knowledge, comprehensive studies examining the effect of protocol
conditions on the resulting oligomer size distribution are not available in the literature to
our knowledge. In addition, it is not a common practice to verify the composition of the
Aß oligomers prior to use, partly due to the limitations in techniques available for fast and
simple Aß multimer characterization.

Currently, the most common means for oligomer quantification is gel electrophoresis [27].
The technique depends on the ability for SDS to bind to proteins of interest. This binding
compromises the structural integrity of proteins resulting in dissociation of oligomer
composition [28]. Low sample throughput and prevalence of gel smearing are also
significant issues which act as limitations in resolution and possess accuracy issues [29].
Another prominent issue gel electrophoresis possesses is the inability to accommodate for
a large mass range for multimer analysis. The percent composition of acrylamide within
the gel is tailored for the target sample. The larger the peptide or protein under analysis,
the lower the amount of acrylamide used in order to facilitate appropriate separation to
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obtain distinct bands. For samples containing a wide range of molecular weights, the set
acrylamide concentration could not optimally accommodate for both extremes, resulting in
either the smaller molecular weight peptides to run off the gel, or poor resolution of the
larger peptides. Other techniques available to study Aß aggregation include atomic force
microscopy (AFM), surface plasmon resonance (SPR), absorbance and fluorescence [3031]. AFM is generally suitable for detection of large Aß aggregates such as fibrils, but not
the soluble small oligomers. SPR is typically used to detect interactions in amyloid-ligand
binding, but ligand interaction is not selective enough to differentiate oligomers by size.
Likewise, absorbance and fluorescence can detect the bulk presence of oligomers, but lacks
the ability to differentiate between small size differences of Aß oligomers.

Electrospray ionization mass spectrometry (ESI MS) has been widely used as an alternative
label free tool for Aß analysis [32-34]. ESI is capable of transforming the multimeric forms
of amyloidogenic peptides from solvated to gaseous ions as intact non-covalent complexes
[35]. However, the resulting complex ions can possess a wide range of multiple charges;
for example, z = 2 to 10. Oligomers of different sizes can therefore have identical m/z,
making the peak assignment to oligomer sizes a perplexing task [36-37]. To overcome this,
researchers turned to the use of ion mobility spectrometry (IMS), which can resolve the
multimeric complex ions, not only by m/z, but also according to size based on their mobility
in a drift tube [38-40]. In recent years, the combination of IMS with ESI MS has become
an invaluable tool in deciphering the assembly mechanism of Aß oligomers [28, 39, 4145]. While IMS-MS is extremely powerful, the resulting two-dimensional data of drift time
and m/z generally require interpretation by IMS specialists. Hence, its applications remain
limited in the neuroscience community.
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The work described herein focuses on a simpler mode of MS based on matrix assisted laser
desorption ionization (MALDI). In contrast to ESI, MALDI generates gaseous ions of
peptides and proteins predominately in the singly charge state (z = 1). As a result, the
measured m/z values of Aß oligomers directly represent the mass of the oligomers. To our
knowledge, Van Duyne et al. presented the first use of MALDI MS to detect oligomers of
Aß1-42, but the use of MALDI MS was not the focus of their work, and only one mass
spectrum of the oligomers was presented as a supplementary figure [46]. Also, the adoption
of this application has not been observed in the literature. Most importantly, the authors
did not present validation experiments to confirm that the observed Aß complex ion
distribution indeed reflect that of original oligomeric Aß sample solution. In the work
described herein, we will examine the validity of MALDI MS in measuring the
composition of Aß multimers. Particularly, we aim to rule out the non-specific associations
of Aß peptides, either during sample preparation or during the MALDI process, which
could produce artificial Aß complexes non-existent in the original sample. To achieve this,
we manipulated the size distribution of Aß oligomer samples using molecular weight cut
off filters, and subsequently illustrated the expected changes in the resulting MS data. After
validating MALDI MS in measuring Aß multimeric composition, the method has been
applied to examine the Aß samples prepared using published protocols on monomerization
and oligomerization for in vitro toxicity assays.
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4.2 Experimental
4.2.1 Apparatus

Aß samples were filtered using 10 kDa and 30 kDa MWCO filters purchased from Pall
Corporation (Ann Arbor, MI), followed by use of Centrifuge 5417c from Eppendorf
(Westbury, NY). ThermoFisher Scientific NanoDropTM Spectrophotometer 2000c
(Waltham, MA) was used to assess the final filtrate concentration of Aß samples after
filtration. All MALDI MS sample analyses were performed on a Sciex TOF/TOF 5800
MALDI mass spectrometer equipped with a 1 kHz OptiBeamTM On-Axis Nd:YAG laser
system (Ontario, Canada). All microscopy data was acquired using a Nikon Eclipse Ni-E
microscope with fluorescent filters and a DS-Qi2 monochrome microscope camera. ImageJ
software was used to process and analyze the data collected. Statistical comparisons
between experimental groups were performed using the GraphPad Prism software. A twoway ANOVA with Tukey’s HSD test was applied.

4.2.2 Samples and Reagents

All Aß peptides were purchased from Bachem (King of Prussia, PA). Ethanol, methanol,
and acetonitrile (ACN) were purchased from Caledon (Ontario, Canada), and hexafluoro2-propanol (HFIP), dimethyl sulfoxide (DMSO), Sinapinic acid (SA), trypsin,
amphotericin B solution, 7% poly-L-ornithine from Sigma Aldrich (St. Louis, MO).
Phosphate buffered saline (PBS) was purchased from Quality Biologicals (Gaithersburg,
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MD).

Ham’s

F-12

nutrients

mixture,

B27

supplement,

N2

supplement,

penicillin/streptomycin, glutamax, and 4’-6-diamidino-2-phenylindole (DAPI) were
purchased from Life Technologies (Grand Island, NY). Formic acid, ammonium hydroxide
was obtained from EM Science (Darmstadt, Germany), and trifluoroacetic acid (TFA) was
purchased from Fischer Scientific (Ottawa, ON, Canada). Neurons were isolated from
Wistar rats purchased from Charles River (Montreal, QC, Canada), Hank’s balanced salt
solution (HBSS) and neural basal media from Wisent (St. Jean-Baptiste, QC, Canada),
Trypsin inhibitor from Roche Life Sciences (Indianapolis, IN) and propidium iodide (PI)
was purchased from Biotium (Hayward, CA).

4.2.3 Amyloid Beta Sample Preparation

Aß peptides were suspended in one of the lyophilization solvents (NH4OH, TFA, HCO2H,
or HFIP) at a concentration of 1 mM to facilitate monomerization. To prepare for short
term storage, the sample was fractionated in 10 μL aliquots and lyophilized for 1 hour at
– 100 oC and stored at – 80 oC. To prepare for use, each aliquot of lyophilized powder was
resuspended in 10 μL of DMSO and sonicated in a 37 oC water bath for 10 minutes. The
sample was then brought to a concentration of 150 μM with the selected incubation solvent
(F12, PBS, or H2O) and vortexed. The solution was incubated at 4oC for 24 hours to
facilitate oligomerization.
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4.2.4 Molecular Weight Cut-Off Filtration

Aß samples monomerized in NH4OH followed by resuspension in either PBS, or H2O were
used for MWCO Filtration assessments. Aliquots of 70 μL were pipetted into each filter
and centrifuged 4 times in 30 second intervals at 14 000 rpm with Centrifuge 5417c from
Eppendorf (Westbury, NY). Once filtered, 1 µL of each sample filtrate was pipette onto the
NanoDropTM spectrophotometer. The A280 protein/peptide analysis software was used to
assess the concentration of each filtrate through monitoring the absorbance at wavelength
(λ) 280 nm. MWCO Filters at 10 kDa and 30 kDa were purchased from Pall Corporation
(Ann Arbor, MI).

4.2.5 Amyloid Beta Toxicity for Embryonic Rat Cortical Neuron Cultures

Aß samples lyophilized in NH4OH and resuspended in DMSO and F12 medium to 150 µM
was used. An Aß1-42 sample was prepared and incubated for 24 hours while a second sample
was prepared at the time of use providing the oligomer and monomer conditions
respectively. Three different environmental conditions were provided for each cell
population (n = 4) with 10 μL additions of pre-incubated Aß1-42 (monomer), and post
incubation Aß1-42 (oligomer). One set of cultures were left without any environmental
alterations to provide a baseline (control) of the natural decrease in cellular viability over
time. The cells were incubated for 6, 24, 36, and 48 hours. PI staining was applied through
addition of 10 μL of PI 45 minutes prior to fixation. The cells were fixed with 500 μL of
4% formaldehyde followed by 400 μL of 2% formaldehyde. The fixing agent was removed
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with 3 consecutive 1x PBS washes. Fine tweezers were used to plate the cells fixed on 12
mm round cover slips. The cells were counter-stained with DAPI for nuclear visualization
and imaged were acquired at 20x magnification. Five images were acquired for each cell
culture in order to obtain the average cell deaths vs. total cells per culture.

4.2.6 MALDI MS Analysis

SA matrix was prepared to 10 µg/µL in 50% ACN and 0.05% TFA. The Aß sample and SA
matrix were deposited as sandwiched layers, where 0.75 μL of the Aß solution was spotted
between two layers of SA (0.75 μL). The spots were washed twice with 1 μL water prior
to analysis. The TOF TOF Series Explorer in positive ion linear mode and Data Explorer
were used for data acquisition and processing respectively.

4.3 Results and Discussion
4.3.1 MALDI MS Detection of Aß1-42 and Aß1-40 Oligomer Composition

We began our studies by reproducing the detection of Aß oligomers with MALDI MS based
on the conditions reported by Van Duyne [46]. Briefly, hexafluoro-2-propanol (HFIP) and
F12 medium were respectively the monomerization and oligomerization buffers. Sinapinic
acid (SA) was the MALDI matrix, and the same spotting was used with a modification of
including a washing step. Effects of different TFA concentrations in the matrix solution
was assessed, and we concluded that a reduction in TFA concentrations was most beneficial
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in the detection of oligomers within the sample. This coincides with previous studies
indicating low pH disruptions in the formation of non-covalent complexes [47-48]. The
instrument’s acquisition parameters were set to optimize for detection sensitivity.

Additional to studying oligomers from Aß1-42, we also included the commonly studied Aß140.

Similar results confirming the successful detection of Aß oligomers of various sizes

were observed for both Aß1-40 and Aß1-42. The mass spectra from Aß1-40 and Aß1-42 oligomers
are shown as Figure 4.1. The monomeric Aß1-40 and Aß1-42 peptides have a molecular
weight of 4329.86 Da and 4514.10 Da respectively. Doubly charged monomers and trimers
were not observed, the mass spectrum therefore displayed signals from singly charged ions
from monomers up to 7-mer and 11-mer when the full mass range up to 50 kDa was
acquired for Aß1-42 and Aß1-40 respectively. Compared to the prior report on MALDI MS
results of Aß oligomers [46], the same overall trend in oligomer size distribution was
detected. Specifically, the monomer and dimer signals were the strongest with the dimer
peak slightly higher in intensity. The signals dropped off in a similar decay fashion for
larger complexes, although higher peak intensities from the larger oligomers were shown.
Differences in sensitivity could be attributed to the different MALDI mass spectrometers
used. The MALDI results also generally agree with those reported by gel electrophoresis,
where substantial quantities of multimers relative to the monomer were typically detected,
as bands of similar size and darkness. The sensitivity was however much higher for
MALDI MS, as it required only 0.5 g per run, compared to the typical 190 – 100 g per
run in gel electrophoresis. When compared to ESI MS, rather different looking mass
spectra were reported with similar samples. A dominant peak corresponding to the
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monomer, with a 3 charge state, is typical in the ESI spectra of Aß1-42. The sum of all
oligomeric peaks were only a minor part of the total response [42].

4.3.2 Validation of MALDI MS Detection Capabilities

To prepare for MALDI MS analysis, sample solutions were mixed with laser absorbing
matrices, deposited as microliter-volume droplets on target plates, and allowed to dry.
Hence, a common concern in the MALDI MS characterization of complexes is the
possibility of artificial non-specific associations during drying. In the literature, numerous
examples of MALDI MS application on complexes of biomolecules were reported and
reviewed [47, 49-50]. The consensus is that the technique is capable of detecting certain
non-covalent multimeric complexes under optimized conditions. However, there is not one
universally optimal protocol. Therefore, it is important to experimentally verify that the Aß
non-covalent complexes detected by MALDI MS herein were not an artifact caused by
non-specific associations that occurred either during sample spot drying or within the mass
spectrometer in gas phase.
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1mer

2mer

1mer
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Figure 4.1 Mass spectra of oligomers prepared from Aß1-42 (A-B) and Aß1-40 (C-D)
displayed singly charged ions upon analysis of the full mass range (A, C). Exclusion of the
monomer (B, D) resulted in oligomers up to 50 kDa in mass observed.
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4.3.2.1 Analysis of Aß Fragments with Various Propensities for Oligomerization

To achieve this, modified Aß1-40 samples with different oligomerization propensities used
in toxicity experiments were investigated. Oligomerization of wild-type Aß1-40 sample was
compared to a scrambled Aß1-40 sequence, and (Gln22) Aß1-40 (Figure 4.2). Scrambled Aß140

samples are used in AD research as inactive controls, and therefore does not have an

affinity for oligomerization [51]. In contrast, (Gln22) Aß1-40 (E22Q) is a mutation which
replaces Glu22 with Gln22, this mutation of Aß was found to aggregate more readily in
comparison to the wild-type peptide [52-55]. The resulting MS data presented in Figure
4.2 reflect the reported variation in oligomerization affinities. Focus was placed starting
from the expected m/z of the dimer in order to focus comparison on oligomer composition
within samples. Through comparison of these three peptide samples, minimal
oligomerization limited to presence of a dimeric peak was detected for scrambled Aß1-40
peptide, while the E22Q mutation clearly presented a much higher propensity for
oligomerization in comparison to the wild-type.
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4.3.2.2 Molecular Weight Cut-Off Filtration Analysis

Additional validation was achieved through manipulation of the Aß1-40 oligomer
composition by passing them through molecular weight cut-off (MWCO) filters at either
10 kDa or 30 kDa cut-off points. The 10 kDa cut-off filter should in theory remove
complexes larger than dimers (8659.72 Da). The resulting mass spectrum indeed revealed
the expected reduction in signals from the large oligomers (Figure 4.3). A moderate
suppression of the dimer signal was also observed. In comparison, when the Aß1-40
oligomers were filtered at the 30 kDa cut-off point, the monomer to dimer and trimer ratios
were largely unchanged. Signal reduction was observed for tetramer (m/z 17,320.44) and
larger species. Taking into account of non-specific adsorption and imprecision in filter cutoff points, the collective MS results were found to be in agreement with the expected
changes in oligomer composition resulting from the MWCO treatments.
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Figure 4.2 Oligomerization of wild-type Aß1-40 (A) was compared to scrambled Aß1-40
(B), and mutated (Gln22) Aß1-40 (C). Through comparison, modifying Glu22 with Gln22 in
the peptide sequence resulted in an Aß1-40 peptide which aggregates much more readily
while the scrambled version of the peptide produced minimal to no oligomerization.
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Figure 4.3 Mass spectra of oligomerized Aß1-40 after passing through 10 kDa (A) and 30
kDa (B) filters. Prior to filtration, oligomeric peaks up to 50 kDa were observed. After
filtration, peaks detected correlate directly with the filter size used.
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The effects of reduction in sample concentration following MWCO treatments were
addressed through determination of final filtrate concentration followed by serial dilutions
of standard Aß1-40 samples. The filtrate concentration was found to be approximately three
times lower than stock concentrations. Respective dilution of stock samples were analyzed
and a full range of oligomers were detected (Figure 4.4). This allowed us to draw the
important conclusion that, despite the harsh, non-native, nature of MALDI MS, it is capable
of revealing the oligomeric composition of Aß complexes in solution. The results in Figure
4.3 did not support any significant levels of non-specific associations of Aß. The Aß
complexes detected by MALDI closely agreed with expected oligomeric compositions of
the solution samples. Finally, the intensity of the MALDI MS signals of these oligomers
corresponded to their concentration at least in a semi-quantitative fashion. It is however
noteworthy that the detection of very large Aß oligomers, if present, is limited by the
sensitivity of the MS.
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Figure 4.4 Oligomer samples of Aß1-40 were prepared and diluted to 50 µM
concentrations. Oligomer detection was not compromised from dilutions indicating loss of
sample during filtration process would not result in results obtained.
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4.3.3 Effects of Variations Among Amyloid Beta Preparatory Protocols

Having established MALDI MS to be a technique that can gauge the composition of Aß
oligomers, we aim to further demonstrate its capability as a quality control methodology
that monitors the on-set of in vitro Aß oligomerization. As previously mentioned, there are
several published protocols of in vitro preparation of Aß oligomers [56-62]. All of them
involve the two major steps of; firstly, solubilizing the lyophilized Aß as presumably
monomers; and secondly, incubating the samples for oligomer formation. However, a
noticeable difference among published protocols is the choice of solvents or solutions in
facilitating these two monomerization and oligomerization steps. Yet the assessment of
possible differences in the resulting samples has not been reported to our knowledge.
Hence, we conducted the investigation with MALDI MS, first looking at the effect of the
monomerization condition followed by that of the oligomerization condition.

4.3.3.1 Monomerization Solvents

The purpose of the monomerization step is to break up previously formed Aß clusters, and
in turn, to promote the formation of ß sheets upon oligomerization. Aß has a high affinity
for oligomerization as a result of the hydrophobic amino acid composition. When in
aqueous environments, aggregation provides the stability needed therefore making the
initial monomerization a crucial step preceding oligomerization. The Aß clusters must be
broken apart prior to the formation of the desired ß sheets of the oligomer structure. The
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commonly used solvents or solutions are, hexafluoro-2-propanol (HFIP), HCO2H, and
trifluoroacetic acid (TFA). Acidic solvents provide the low pH which disrupts the
quaternary structure of non-covalent complexes. HFIP, HCO2H, and TFA are believed to
remove Aß non-specific aggregates and fibrils within a sample [63]. In addition, we also
included NH4OH in this studies, which was believed to promote monomerization of Aß
and thus others have recently adopted its use [24-25, 59-60]. To begin our assessment, four
Aß samples were prepared with each of these four solvents and lyophilized. MALDI MS
analysis was then performed on the resulting “monomerized” Aß samples. To enhance the
sensitivity in the detection of the non-covalent complexes, the spectra were re-acquired
beginning at 6500 Da for the purpose of reducing the suppressing effects from the
saturating signals of the monomer. The mass spectra shown in Figure 4.5 were each
normalized to its monomer intensity. The results revealed that significant amounts of
multimers were present in the “monomerized” samples prepared from all three of the most
commonly used protocols (HFIP, HCO2H, and TFA). The oligomeric complexes were most
noticeable from samples prepared with HFIP and HCO2H. Only the Aß sample prepared
with NH4OH resulted in predominantly monomers. This somewhat unexpected finding
illustrates the importance of verifying the Aß composition prior to use.
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Figure 4.5 Mass spectra of Aß1-40 after treatment with four monomerization solutions:
HFIP (A), HCO2H (B), TFA (C) and NH4OH (D). To enhance the sensitivity in the
detection of the larger oligomers, the upper spectra were acquired beginning at 6500 Da
for the purpose of reducing the suppressing effects from the monomers.
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4.3.3.2 Oligomerization Solvents

The effect of the oligomerization condition on Aß oligomer composition was examined
next. Among the published protocols, PBS and Ham’s F12 medium were most widely used
in oligomeric Aß preparation [46, 58, 61, 64]. Additional to these two solutions, we also
included the use of deionized water in the comparison. Using these three oligomerization
solutions, we performed incubation on each of the four samples monomerized by HFIP,
HCO2H, TFA and NH4OH. Our MALDI MS results revealed a substantial degree of
oligomerization across all four samples, in all three oligomerization solutions. The four
sets of mass spectra were essentially indistinguishable from one another, and so only the
results from the HFIP-monomerized sample are shown as an example (Figure 4.6). HFIP
was selected as it was most commonly used in literature. The oligomer distributions from
the three oligomerization solutions in Figure 4.6 were not distinctly different from each
other. Hence, we concluded that the choice of the oligomerization solvent/solution was not
a critical factor to the extent of oligomer formation. We believe that Aß favors the
oligomerized state due to the protein’s hydrophobic characteristics, and therefore
oligomerization proceeded spontaneously and favorably regardless of the choice of solvent
or solution. However, the critical factor resides in the incubation period needed to facilitate
the formation of oligomers. When compared with MS results prior to incubation,
significantly stronger signals from multimers were observed following incubation.
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Figure 4.6 Mass spectra of oligomerized Aß1-40 prepared in two oligomerization
solutions, PBS (blue) and F12 (green), and in water (red).
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4.3.4 In Vitro Amyloid Beta Toxicity Assessment

Aside from determining which monomerization or oligomerization conditions work best
for Aß, the more critical message of this work is the importance of experimentally verifying
the composition of Aß multimers prior to use. In this case, all three of the most commonly
used monomerization protocols actually resulted in significant amounts of Aß oligomers;
namely a 20-25% dimer to monomer ratio was observed after monomerization, which
overlaps with 25-30% ratio observed after oligomerization. Given that the oligomeric form
of Aß is mainly responsible of its deleterious effect on neurons, the use of such false Aß
“monomers” would have led to results conflicting with the literature. To illustrate this
point, data from an in vitro toxicity assay on embryonic rat cortical neuron cell cultures are
presented. The average cell death percentage was determined in 48 hours under the
treatment of Aß oligomers and the verified Aß monomers prepared by NH4OH, and a
control of no treatment was also included (Figure 4.7). The results obtained from the
monomer treatment were indistinguishable from the control in all time points measured. In
contrast, an accelerated rate of cell death was observed upon treatment with Aß oligomers.
At 24 hours, the toxicity of the oligomer sample treatment began to display a notable
difference when compared to the monomer sample (P = 0.07). As the treatment was
extended for 36 hours, the toxicity of the oligomer treatment was significantly higher than
that of the control (P = 0.002). Once the treatment was carried out for 48 hours, statistically
significant differences in toxicity between the oligomeric sample and that of the control
and monomeric samples were observed (p = 0.03 and 0.01 respectively). In the literature,
reports on the effect of Aß oligomers varied depending on conditions such as cell culture
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preparation methods, stains, and dosage. For example, one reported a decrease in cellular
viability from 90% to 55% upon exposure to Aß oligomers while another reported 20%
cellular viability after 48 hours [65-66]. Importantly, our results reaffirmed the significant
toxicity of the oligomeric form of Aß, in comparison to the monomeric Aß and the control,
and MALDI MS played an important role of rapid validation of Aß sample composition
for the toxicity experiments.
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Figure 4.7 Rat cortical neuron cell death determined under the treatment of Aß1-42
monomers and oligomers. Results are presented as the mean with S.E.M. (n=4). *: P ≤
0.05, **: P ≤ 0.01 (two-way ANOVA with Tukey’s HSD test).
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4.4 Conclusion
In this work the capabilities of MALDI MS as a sensitive, fast, and simple method in the
detection of in vitro Aß oligomers was demonstrated. The results were validated through
use of MWCO filters to ensure the MS data reflects the sample composition in solution.
The methodology allowed us to investigate the effect of preparation conditions on the
resulting monomeric/multimeric composition, particularly in tracking the onset of
oligomerization by monitoring the formation of 2-mer to 10-mer. In terms of applications,
MALDI MS allows researchers to quickly characterize their Aß multimeric composition
prior to studying their role in neurodegeneration, and/or evaluating potential
neuroprotective agents against Aß. The importance of quality control on the Aß
composition was demonstrated through an in vitro toxic assay on neuron culture, where
MALDI MS played a critical role in identifying a fully monomerized sample of Aß. Finally,
the detection of Aß oligomers with MALDI MS presents an exciting opportunity for ex
vivo characterization of Aß extracted from the brain, or direct MALDI MS imaging of
multimeric Aß in brain tissues, although further research and development is required to
overcome the potential issue of background interferences and signal suppression.

145

4.5 References
[1]
Murphy, S. L.; Xu, J.; Kochanek, K. D.; National vital statistics reports : from the
Centers for Disease Control and Prevention, National Center for Health Statistics, National
Vital Statistics System 2013, 61 (4), 1-117.
[2]
32.

Lauren, J.; Gimbel, D. A.; Nygaard, H. B., et al.; Nature 2009, 457 (7233), 1128-

[3]
948.

Wilcox, K. C.; Lacor, P. N.; Pitt, J., et al.; Cell Mol Neurobiol 2011, 31 (6), 939-

[4]
Crescenzi, O.; Tomaselli, S.; Guerrini, R., et al.; European Journal of Biochemistry
2002, 269 (22), 5642-5648.
[5]
Gong, Y.; Chang, L.; Viola, K. L., et al.; Proceedings of the National Academy of
Sciences 2002, 100 (18), 10417-10422.
[6]

Harman, D.; Journal of the American Aging Association 2000, 23 (3), 147-161.

[7]
224.

Klein, W. L.; Krafft, G. A.; Finch, C. E.; Trends in Neurosciences 2001, 24 (4), 219-

[8]

Viola, K. L.; Klein, W. L.; Acta Neuropathol 2015, 129, 183-206.

[9]
Kotilinek, L. A.; Bacskai, B.; Westerman, M., et al.; Journal of Neuroscience 2002,
22 (15), 6331-6335.
[10] Giordano, C. R.; Terlecky, L. J.; Bollig-Fischer, A., et al.; Scientific Reports 2014,
4 (4983).
[11]

Walsh, D. M.; Klyubin, I.; Fadeeva, J. V., et al.; Nature 2002, 416 (6880), 535-539.

[12]

Ferreira, S. T.; Klein, W. L.; Neurobiol Learn Mem 2011, 96 (4), 529-543.

[13] Hung, L. W.; Ciccotosto, G. D.; Giannakis, E., et al.; Journal of Neuroscience 2008,
28 (46), 11950-11958.
[14] Dahlgren, K. N.; Manelli, A. M.; Stine, W. B., Jr., et al.; J Biol Chem 2002, 277
(35), 32046-53.
[15] Stroud, J. C.; Liu, C.; Teng, P. K., et al.; Proc Natl Acad Sci U S A 2012, 109 (20),
7717-22.

146

[16]

Hardy, J.; Selkoe, D. J.; Science 2002, 297 (5580), 353-356.

[17]

Trimpin, S.; Deinzer, M. L.; J Am Soc Mass Spectrom 2007, 18 (8), 1533-43.

[18] Ebenezer, P. J.; Weidner, A. M.; LeVine, H., et al.; Journal of Alzheimers Disease
2010, 22 (3), 839-848.
[19]

Ai, Z. B.; Li, C. Y.; Li, L. T., et al.; Mol Med Rep 2015, 11 (4), 2429-2434.

[20]

Alomari, A. K.; Glusac, E. J.; Choi, J., et al.; J Cutan Pathol 2015, 42 (10), 757-64.

[21]
112.

Cizas, P.; Jekabsone, A.; Borutaite, V., et al.; Medicina-Lithuania 2011, 47 (2), 107-

[22] Kelley, A. R.; Perry, G.; Castellani, R. J., et al.; ACS Chem Neurosci 2016, 7 (3),
261-268.
[23]

Jan, A.; Hartley, D. M.; Lashuel, H. A.; Nat Protoc 2010, 5 (6), 1186-1209.

[24]

Ryan, T. M.; Caine, J.; Mertens, H. D., et al.; PeerJ 2013, 1, e73.

[25]
33.

Teplow, D. B.; Amyloid, Prions, and Other Protein Aggregates, Pt C 2006, 413, 20-

[26] Broersen, K.; Jonckheere, W.; Rozenski, J., et al.; Protein Engineering Design &
Selection 2011, 24 (9), 743-750.
[27] Bitan, G.; Fradinger, E. A.; Spring, S. M., et al.; Amyloid-Journal of Protein
Folding Disorders 2005, 12 (2), 88-95.
[28]

Pryor, N. E.; Moss, M. A.; Hestekin, C. N.; Int J Mol Sci 2012, 13 (3), 3038-3072.

[29] Bitan, G.; Lomakin, A.; Teplow, D. B.; Journal of Biological Chemistry 2001, 276
(37), 35176-35184.
[30] Amaro, M.; Kubiak-Ossowska, K.; Birch, D. J., et al.; Methods and Applications in
Fluorescence 2013, 1 (1), 1-13.
[31] Lindberg, D. J.; Wranne, M. S.; Gatty, M. G., et al.; Biochem Biophys Res Commun
2015, 458 (2), 418-423.
[32] Bleiholder, C.; Dupuis, N. F.; Wyttenbach, T., et al.; Nature Chemistry 2011, 3 (2),
172-177.
[33] Grasso, G.; Mineo, P.; Rizzarelli, E., et al.; Int J Mass Spectrom 2009, 282 (1-2),
50-55.

147

[34] Martineau, E.; de Guzman, J. M.; Rodionova, L., et al.; J Am Soc Mass Spectrom
2010, 21 (9), 1506-1514.
[35]

Vrana, J. A.; Theis, J. D.; Dasari, S., et al.; Haematologica 2014, 99 (7), 1239-1247.

[36]

Smith, A. M.; Jahn, T. R.; Ashcroft, A. E., et al.; J Mol Biol 2006, 364 (1), 9-19.

[37]

Ashcroft, A. E.; J Am Soc Mass Spectrom 2010, 21 (7), 1087-1096.

[38] Henderson, S. C.; Valentine, S. J.; Counterman, A. E., et al.; Anal Chem 1999, 71
(2), 291-301.
[39] Hoaglund, C. S.; Valentine, S. J.; Sporleder, C. R., et al.; Anal Chem 1998, 70 (11),
2236-2242.
[40] Ionut Iurascu, M.; Cozma, C.; Tomczyk, N., et al.; Anal Bioanal Chem 2009, 395
(8), 2509-19.
[41] Bernstein, S. L.; Dupuis, N. F.; Lazo, N. D., et al.; Nature Chemistry 2009, 1 (4),
326-331.
[42] Bernstein, S. L.; Wyttenbach, T.; Baumketner, A., et al.; J Am Chem Soc 2005, 127
(7), 2075-2084.
[43] Baumketner, A.; Bernstein, S. L.; Wyttenbach, T., et al.; Protein Science 2006, 15
(3), 420-428.
[44] Zheng, X. Y.; Liu, D.; Klarner, F. G., et al.; Journal of Physical Chemistry B 2015,
119 (14), 4831-4841.
[45]

Illes-Toth, E.; Smith, D. P.; Current Analytical Chemistry 2013, 9 (2), 165-180.

[46] Anker, J. N.; Hall, W. P.; Lambert, M. P., et al.; Journal of Physical Chemistry C
2009, 113 (15), 5891-5894.
[47]

Cuburu, N.; Kweon, M. N.; Song, J. H., et al.; Vaccine 2007, 25 (51), 8598-8610.

[48]

Song, F. H.; J Am Soc Mass Spectrom 2007, 18 (7), 1286-1290.

[49] Madler, S.; Erba, E. B.; Zenobi, R.; Applications of Maldi-Tof Spectroscopy 2013,
331, 1-36.
[50]
704.

Farmer, T. B.; Caprioli, R. M.; Journal of Mass Spectrometry 1998, 33 (8), 697-

148

[51]

Ji, Y.; Permanne, B.; Sigurdsson, E. M., et al.; J Alzheimers Dis 2001, 3 (1), 23-30.

[52]

Solito, R.; Corti, F.; Fossati, S., et al.; Exp Cell Res 2009, 315 (3), 385-395.

[53]
340.

Kumar-Singh, S.; Julliams, A.; Nuydens, R., et al.; Neurobiol Dis 2002, 11 (2), 330-

[54] Munoz, F. J.; Opazo, C.; Gil-Gomez, G., et al.; Journal of Neuroscience 2002, 22
(8), 3081-3089.
[55]

Wang, Z. Z.; Natte, R.; Berliner, J. A., et al.; Stroke 2000, 31 (2), 534-538.

[56] Young, K. F.; Pasternak, S. H.; Rylett, R. J.; Neurochemistry international 2009, 55
(8), 796-801.
[57]
605.

Lambert, M. P.; Viola, K. L.; Chromy, B. A., et al.; J Neurochem 2001, 79 (3), 595-

[58]
847.

Barghorn, S.; Nimmrich, V.; Striebinger, A., et al.; J Neurochem 2005, 95 (3), 834-

[59] Rangachari, V.; Moore, B. D.; Reed, D. K., et al.; Biochemistry 2007, 46 (43),
12451-12462.
[60] Moore, B. D.; Rangachari, V.; Tay, W. M., et al.; Biochemistry 2009, 48 (49), 1179611806.
[61] Lambert, M. P.; Barlow, A. K.; Chromy, B. A., et al.; Proc Natl Acad Sci U S A
1998, 95 (11), 6448-6453.
[62] Risse, E.; Nicoll, A. J.; Taylor, W. A., et al.; Journal of Biological Chemistry 2015,
290 (27), 17020-17028.
[63]

Stine, W. B.; Jungbauer, L.; Yu, C., et al.; Methods Mol Biol 2011, 670, 13-32.

[64] Chromy, B. A.; Nowak, R. J.; Lambert, M. P., et al.; Biochemistry 2003, 42 (44),
12749-12760.
[65]
486.

Morkuniene, R.; Cizas, P.; Jankeviciute, S., et al.; J Neurosci Res 2015, 93 (3), 475-

[66]

Zou, K.; Kim, D.; Kakio, A., et al.; J Neurochem 2003, 87 (3), 609-619.

149

Chapter 5: Enhancements in Detection Sensitivity for
the Amyloid Beta Protein with Matrix-Assisted Laser
Desorption/Ionization Mass Spectrometry Imaging
(MALDI MSI)
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5.1 Introduction
5.1.1 MALDI MSI of Proteins in Intact Tissue Sections

The development of MALDI matrix application methods has come a long way. From
initially pipetting a large droplet of matrix to cover the target sample area, to the
development of automated sprayers, these advancements and innovations have made it
possible to obtain images of high spatial and signal resolution for lipids, and small
molecules [1-6]. This technique can provide information regarding spatial distribution for
a wide range of analytes within a single sample, as well as provide a means for untargeted
analysis of complex tissue sections [7-11]. Although much progress has been made in the
development of MALDI MSI, limititations still exist in the detection sensitivity for low
abundance analytes within biological samples. In comparison to lipids and other small
molecules, intact proteins are more difficult to extract form tissue sections making imaging
of proteins a more challenging task in comparison.

Integration of MALDI MSI into the proteomics field has been hindered by the poor
detection sensitivity of low abundant proteins and peptides within the complex molecular
composition of each tissue sample [12]. The high concentrations of salts, lipids, and
metabolites in comparison cause ion suppression effects, and therefore development of
sample preparation methods becomes critial in determining the success or failure of these
imaging experiments. Ion suppression results from numerous competing factors that can
have a negative effect on the extraction, desorption, and ionization of target analytes within
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a sample [13]. There are two types of sample related ion suppression effects with MALDI
MS, matrix suppression, and analyte suppression [14]. However, matrix suppression poses
as a greater effect when analyzing compounds with a lower m/z. Therefore, when looking
at proteins, understanding sample composition and identifying compounds that could cause
ion suppression of your target analyte is of greater importance. Expansion and development
of suitable sample preparation techniques along with determination of appropriate
instrumental parameters can assist in the detection of intact proteins within tissue samples.

The analysis of Aß1-42 has been proposed to address the difficulties in the detection and
localization of this protein. Aß1-42 is a small, hydrophobic protein with a mass of 4514.10
Da. The complications in working with Aß experimentally is caused by its instability in
aqueous conditions which lead to rapid aggregation. Here, focus has been placed on
enhancements in detection sensitivity of the intact Aß1-42 proteins through use of solidphase extraction techniques. We aim to utilize magnetic C18 beads as a means for Aß
extraction, while simultaneously retaining the Aß distribution within intact brain sections.

5.1.2 Magnetic Bead Solid - Phase Extraction

Solid - phase extraction (SPE) has become one of the most commonly used sample
preparation techniques for isolation, and enrichment of target analytes [15]. This technique
helps to isolate analytes from complex mixtures which may possess compounds that could
prevent the detection and analysis of the target analyte. SPE has gained popularity as a
result of its simple execution protocols, and the reduction of solvents needed for sufficient

152

extraction [16-17]. In comparison to liquid - liquid extraction techniques, SPE delivers a
more efficient separation providing higher recovery of analytes [18]. Traditionally, SPE
techniques involve a stationary phase, and a mobile phase consisting of the analyte mixture.
Efficient analyte isolation or enrichment is dependent on the selection of a suitable
stationary phase. The various types of SPE available are: reverse phase, normal phase, and
ion exchange [19]. With reverse phase (RP) SPE, the stationary phase is nonpolar while
the mobile phase is polar. RP SPE is most suitable when the target analyte is a moderate to
nonpolar compound which can be retained on the stationary phase until a nonpolar solvent
is used for elution. Normal phase (NP) SPE is the opposite, with the stationary phase being
polar while mobile phase is nonpolar, therefore targeting polar analytes. With ion exchange
SPE, the main interaction is based on the electrostatic attraction of a compound's charged
functional groups with the charged groups bound to the silica surface of the stationary
phase.

In this work, we use RP SPE to facilitate extraction of Aß from the brain tissue surface in
order to enhance the sensitivity of MALDI MSI. RP SPE should be highly effective for the
hydrophobic Aß proteins, however traditional SPE columns would not be useful in this
instance since the samples of interest are intact brain tissue sections. Instead, the
application of loose magnetic beads directly on tissue sections has been proposed.
Magnetic beads provide an alternative to chromatography columns, spin columns and pipet
tip sample preparation techniques [20-21]. In theory, the beads will extract hydrophobic
proteins such as Aß off from the tissue surface, while the application of the organic matrix
solvent will cause the proteins to essentially “elute” off of the beads. This process should
improve the efficiency of the co-crystallization process between Aß and the matrix. In
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terms of sample preparation, magnetic beads can be fixed in a stationary position with a
magnet, while tissue washing procedures are performed to remove unwanted contaminants.
This prevents loss of the protein during preparatory steps prior to analysis, and will also
preserve the anatomical locaton of target analytes allowing for a more rigorous tissue
washing approach. Overall, this technique should improve the resulting detection
sensitivity of proteins like Aß within intact tissue for MALDI MSI analysis.

5.2 Experimental
5.2.1 Apparatus

All MALDI MS sample analyses were performed on a Sciex TOF/TOF 5800 MALDI mass
spectrometer equipped with a 1 kHz OptiBeamTM On-Axis Nd:YAG laser system (Ontario,
Canada). The TOF TOF Series Explorer and Data Explorer were used for data acquisition
and processing respectively. The Sciex TOF TOF Imaging software was used for region
selection and image data collection. All MALDI MSI data was processed and analyzed
using MathWorks MATLAB MSiReader software.

Matrix was applied using HTX Technologies automated TM Sprayer system (Chapel Hill,
NC). A CryoStar NX50 from ThermoFisher Scientific (Ontario, Canada) was used for all
tissue slicing. Syringes and Needles used for tissue sample preparation Aß injections were
purchased from Dyna Medical (Ontario, Canada), and Becton - Dickinson & Co (Franklin
Lakes, NJ) respectively. Rehydration chambers were created with Fisherbrand Petri Dishes
from Fisher Scientific (Ontario, Canada), and rehydration was accomplished using a
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Robbins Scientific Micro Hybridization Incubator Model 2000 (San Diego, CA). A High
Performance BH airbrush was purchased from Iwata (Portland, OR) for all airbrush
applications. Deionized water used throughout these experiments were obtained from a
Millipore Milli-Q A10 Water Purification System (Bedford, MA).

5.2.2 Samples and Reagents

Reagent grade acetonitrile (ACN), ammonium hydroxide, and methanol were purchased
from Caledon (Ontario, Canada). HPLC grade ethanol, acetone, and trifluoroacetic acid
(TFA) were purchased from Fischer Scientific Ltd. (Hampton, NH). Ammonium hydrogen
phosphate (AP), α-cyano-4-hydroxycinnamic acid (CHCA), ß-casein, chloroform,
ammonium citrate dibasic, acetic acid, anhydrous dimethyl sulfoxide (DMSO), and
sinapinic acid (SA) were purchased from Sigma-Aldrich (St. Louis, MO). Phosphate
buffered saline (PBS) was purchased from Quality Biologicals (Gaithersburg, MD). Ham’s
F-12 nutrients mixture was purchased from Life Technologies (Grand Island, NY). 4700
calibration mass standards kit was purchased from Applied Biosystems (Foster City, CA).
The Aß1-42 protein was purchased from Bachem (King of Prussia, PA). C18 beads BcMag,
Zip Tips, Dynabeads were purchased from BioClone Inc. (San Diego, CA), Millipore
(Billerica, MA), and Life Technologies (Oslo, Norway) respectively. Pentobarbital Sodium
Injections were purchased from Bimeda MTC Animal Health Inc. (Ontario, Canada).
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5.2.3 Amyloid Beta Sample Preparation

Aß1-42 peptides were suspended in NH4OH and brought to a concentration of 1 mM to
facilitate monomerization. To prepare for short term storage, the sample was fractionated
in 10 μL aliquots, lyophilized for 1 hour at – 100 oC, and stored at – 80 oC. For each use,
an aliquot of lyophilized powder was resuspended in 10 μL of anhydrous DMSO, and
sonicated in a 37 oC water bath for 10 minutes. The sample was then brought to a
concentration of 150 μM with Ham’s F-12 medium, and vortexed for 30 seconds. The
solution was incubated at 4 oC for 24 hours to facilitate oligomerization.

5.2.4 Variations in Magnetic Bead Extraction Efficiency

Three C18 beads were tested for in-vial extraction efficiency (Figure 5.1). C18 Dynabeads
were assessed along with BcMag and Zip Tips. The 4700 calibration mixture, ß casein
digest, and Aß1-42 samples were used for the assessments. 10 µL of 0.1 µg/µL was prepared
for each sample. 10 µL of each stock bead solution was added to individual epitubes, and
10 µL of each sample was added to corresponding tube and mixed. A binding period of 2
minutes was provided followed by application of magnet to allow for supernatant
removal. 10 µL of wash solution (0.1% TFA) was added and aspirated with a micropipet.
The beads were held constant once again and supernatant removed. After three washes, 6
µL of desorption solution (50% ACN) was added. The mixture was aspirated and
remained at room temperature for 2 minutes followed by removal of the supernatent. This
sample procedure was applied for both BcMag and Dynabeads. The media for Zip Tips
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were contained within 10 µL pipette tips. In order to test the binding efficiency, the tips
were wet with a 50% methanol solution, and equilibrated with a 0.1% TFA solution. Each
sample was aspirated 10 times using individual Zip Tips, followed by aspiration of the
wash solution (0.1% TFA). The proteins and peptides were then eluted with a 60%
acetonitrile solution.
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Figure 5.1 In-vial binding efficiency of BcMag and Dynabead magnetic beads were tested.
Magnetic Beads were added into the sample vial, followed by a binding period. After
which, the beads were held in place by a magnetic, and the supernatant was removed. The
beads were washed three times, followed by addition of an elution buffer to “elute” the
target analytes off of the beads. The resulting solution was then spotted on a MALDI MS
sample plate and analyzed.
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5.2.5 Magnetic C18 Dynabeads on Plate Extraction Efficiency

To test bead compatibility with MALDI MS analysis, 25 µM concentration of Aß1-42 was
premixed with CHCA, and 0.75 µL was spotted on the plate. A second layer of C18
Dynabeads was spotted on top. 12.5 µg/µL stock solution of Dynabead was diluted 5x,
10x, and 15x with water and 0.75 µL of each dilution was spot on a premixed analytematrix spot to assess optimal bead concentration for spot analysis. On plate Aß extraction
potential was evaluated by spotting 0.75 μL of 25 µM, 2.5 μM, and 0.25 μM Aß on a
MALDI plate. Once dried, 0.75 μL of 1.25 μg/μL of Dynabeads were spotted above each
sample spot. CHCA was prepared to 5.5 μg/μL in 50% ACN, 6 mM AP, 0.1% TFA, and a
final layer of CHCA was then spotted.

5.2.6 Sample Preparation for MALDI MSI Analysis

5.2.6.1 Tissue Extraction and Postmortem Amyloid Beta Injections

Transgenic and wildtype Fischer (344) rats were used for these experiments. Once deeply
anaesthetized, rats were euthanized with a pentobarbital overdose, and brain tissue was
extracted using a fresh frozen extraction method [22]. With this method, the rat brain was
not perfused with 4% paraformaldehyde prior to Aß injection, therefore the blood flow to
the tissue was retained. Immediately after tissue removal, the brain tissue was placed on
dry ice and 25 µL of 150 uM Aß solution was injected directly into the cerebral cortex. As
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the syringe was withdrawn, small amounts of sample solution was continuously released
to ensure Aß is present along the entire sagittal section. This guarantees analyte presence
with each coronal tissue section. Once injection was completed, tissue was completely
frozen on dry ice and stored in – 80 oC or sectioned using a cryostat for immediate MALDI
MSI analysis.

5.2.6.2 Tissue Mounting and Preparation

Tissue samples were freeze mounted onto the tissue holder of the cryotostat with water and
sectioned to 14 μm thickness at - 25 oC. Once sectioned, the coronal brain sections were
thaw mounted onto ITO glass slides and placed in a desiccator for 10 minutes. A six step
tissue fixation, wash and acidification procedure was performed. The samples were first
washed by submerging in 70% EtOH solution, followed by 100% EtOH for 30 seconds
each. The slide was then removed and placed for 2 minutes in a solution of 60% EtOH,
30% chloroform, and 10% glacial acetic acid. This was followed by a 30 seconds wash of
100% EtOH. Acidification was achieved through submerging the sample within a solution
of 0.2% TFA for 2.5 minute. A final wash was done using 100% EtOH to remove residual
solvent and water.

5.2.6.3 On Tissue Magnetic Bead Extraction

The stock Dynabead solution was diluted to 1.25 µg/µL with Millipore H2O to make a 3
mL solution. The solution was vortexed for a minute to facilitate dispersion. 0.75 µL of the
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Dynabead solution was pipet onto spiked Aß samples on top of tissue sections for spot
analysis. 1 mL of the Dynabead solution was deposited into the solvent holder of the
airbrush. Airbrush application was used to evenly coat the entire tissue section with the
Dynabead solution. 4 layers were applied with a 30 seconds wait period in between each
layer.

5.2.6.4 Matrix Deposition & Tissue Rehydration

SA matrix was prepared to 10 µg/µL in 50% ACN, and 0.05% TFA Solution. SA was
sprayed onto tissue sections using the TM sprayer. Complete sample coverage was obtained
using 4 passes at a velocity of 1200 mm/min and a flow rate of 0.1 mL/min. The
temperature and pressure were held constant at 70 oC and 12 psi respectively with a 30
second wait period between layers. A final matrix density of 1.67 x 10-3 mg/mm2 was
achieved. When magnetic bead extraction was performed, an additional layer of matrix
solvent was sprayed at a reduced flow rate of 0.05 mL/min. Tissue rehydration was
performed using a 5% acetic acid solution. A metal heat sink was fixed onto the top half of
a petri dish, the sample slide was then fixed onto the heat sink. This portion of the petri
dish was placed in a rehydration chamber set to 70 oC for 30 seconds. A filter paper soaked
in the 5% acetic acid solution was placed on the bottom half of the petri dish. The top and
bottom halves were then sealed together and placed in the rehydration chamber for 3.5
minutes.
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5.2.7 MALDI MSI Parameters

The Sciex TOF TOF imaging software was used to select for regions of interest (ROI).
Once selected, acquisition parameters were selected for the positive ion mode. Protein and
peptide data were acquired in linear and reflectron modes respectively. Images were set up
to a raster size of 70 µm and a total of 35 shots was performed at each fixed sample position.

5.3 Results and Discussion
5.3.1 Enhancement of Detection Sensitivity Facilitated by C18 Magnetic
Bead Extraction

5.3.1.1 Magnetic Bead Selection

In vial assessment of variations in binding capabilities among C18 beads from Millipore,
BioClone Inc, and Life Technologies was performed. Extraction capabilities of the beads
were tested using 0.1 µg/µL samples of ß-casein digest, 4700 calibration peptide mixture,
and Aß1-42. Through comparison, Dynabeads showed to be superior in the binding and
elution capabilities for the scope of samples tested. Of the three beads, BcMag presented
the worst retention and elution capabilities for all samples, with poor binding capabilities
for the Aß sample resulting in the majority of the analyte residing in the supernatant.
BcMag was only capable of recovering three out of five of the peptides within the 4700
calibration mixture. While the ZipTips were great with the recovery of smaller peptides,
Aß samples were not able to elute off of the beads, and therefore presented ion counts of
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less than 100. In comparison, the Dynabeads were capable of recovering the widest range
of samples with the highest recovery for all three samples tested. Therefore, the C18
Dynabeads were selected for further analysis. The magnetic properties of the Dynabeads
also provide an additional platform for control over the bead placements.

Upon selection of the C18 Dynabeads, determination of bead concentration was required
for uniform coverage without reduction of detected signal intensity. 12.5 µg/µL stock
solution of Dynabeads was diluted 5x, 10x, 15x, 20x and spotted onto premixed samplematrix spots on a MALDI MS plate. The spectral data in Figure 5.2 revealed a 50%
decrease in signal intensity when the beads were diluted greater than 10x.

Microscopic images were obtained to visualize bead distribution on sample spots. Uneven
bead dispersion was seen when bead concentration was diluted greater than 10x. Poor
uniformity in bead coverage greatly affect extraction potential for the target sample
throughout the entire section analyzed, and therefore uniform distribution must be taken
into account when optimizing the concentration of beads required. Based on the
microscopic images presented in Figure 5.3, both 5x and 10x dilutions presented fairly
uniform coverage, since signal detection was seen to be relatively similar in intensity, a
1.25 µg/µL concentration of Dynabeads was confirmed to be optimal for further
applications.
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Figure 5.2 Effects of varying Dynabead concentrations applied per sample spot was
assessed. A stock solution of 12.5 µg/µL was diluted 5x (A), 10x (B), 15x (C), and 20x
(D). Aß1-42 signals obtained was evaluated. A reduction of greater than 50% in signal
intensity was observed when bead dilution exceeded 10x, therefore a minimum of 1.25
µg/µL bead concentration per sample spot was determined.
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Figure 5.3 The optimal concentration of C18 Dynabeads was evaluated by visualizing
bead coverage on the sample spot. Upon Dilution of the 12.5 µg/µL stock solution 5x (A),
10x (B), 15x (C), and 20x (D), 5x and 10x dilutions provided the most coverage throughout
the entire sample section.

165

5.3.1.2 Aß Signal Enhancement Effects using C18 Magnetic Beads

C18 Dynabeads utilized the principles of reverse phase chromatography (RPC) to capture
hydrophobic proteins and peptides within mixtures. The beads possessed an iron oxide core
which was coated with silica. The silica surface was modified with hydrophobic alkyl
chains in which target proteins and peptides were bound. Once washed, the bead bound
proteins were eluted into a clean solvent for analysis. Enhancement effects of the C18
magnetic beads were tested using 0.25 µM, 2.5 µM, and 25 µM concentration of Aß1-42
proteins. Each of these samples were spotted onto a MALDI MS sample plate in layered
format along with 1.25 µM C18 Dynabeads, matrix, and solvent. A final layer of matrix
solvent was spotted due to the enhancement effects observed in previous testing. The
additional solvent layer was hypothesized to facilitate protein extraction, and the cocrystallization of the matrix – anayte mixture. From Figure 5.4, minor signal enhancement
effects were observed for concentrations 2.5 µM and 25 µM sample solutions, while
significant enhancement was seen for the detection of the 0.25 µM Aß1-42 sample. A
concentration of 0.25 µM was below the instruments detection threshold for Aß1-42, but
with the help of magnetic bead extraction, a well resolved signal was observed.
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Figure 5.4 On plate extraction of Dynabeads was assessed using different concentrations
of Aß1-42, 0.25 µM (A-B), 2.5 µM (C-D), and 25 µM (E-F). MALDI MS spectra was
obtained before and after bead extraction protocol was applied in order to compare signal
enhancement effects. With Dynabead extraction, signal intensity detected was amplified
for each concentration with the most significant being of the lowest, 0.25 µM
concentration. On bare plate, an Aß concentration of 0.25 µM would have previously gone
undetected without the aid of Dynabeads.
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Following the enhancements observed through spot analysis of Aß on the MALDI MS
sample plates, the detrimental effects of tissue surface composition on Aß signal detection
was addressed by spotting Aß samples with the same concentration range of 2.5 µM – 25
µM on untreated intact tissue sections. Spiked tissue sections were first analysed prior to
direct injection of Aß in order to minimize possible complications such as sample diffusion
within the brain. This allows the signal suppression and enhancement effects observed to
solely be a result of the tissue background and Dynabeads respectively. Figure 5.5 presents
the signal detection capabilities of MALDI MS with and without the Dynabeads. The
abundance in molecules on the tissue surface resulted in poor S/N ratios. Without the
Dynabeads, the contaminants on the tissue surface strongly suppressed the Aß signal to
nearly undetectable levels. However, the Dynabeads were able to enhance signal detection
of the target Aß protein for all concentrations tested. As expected, although enhancement
was observed when Dynabead were used, the effects were severely compromised on tissue
in comparison to when previously tested on the bare plate (Figure 5.4). When detected, the
Aß signal was found to be shifted from 4514.10 Da to ~ 5000 Da. This shift is not
uncommon when MS experiments are performed on tissue samples [23]. The threedimensional structure of these samples influence the ion flight time resulting in
significantly lower resolution and mass accuracy. These effects become more and more
pronounce the larger the target analyte is. Unfortunately, the height difference of the
mounted tissue section can be minimized, but not completely eradicated. The tissue was
also analyzed prior to any Aß sample spotting to ensure the peak observed at ~ 5000 Da is
representative of the Aß sample.
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The enhancement in signals observed support the prior hypothesis that the beads aid in the
extraction of Aß proteins allowing for improved co-crystallization with the MALDI MS
matrix. Significant enhancement effects were most prominent for low Aß concentrations
on bare plate, and on tissue analysis of Aß. The issue of surface contamination when
studying tissue sections can be minimized with additional tissue washing procedures.
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Figure 5.5 On Tissue extraction capabilities of Dynabeads were assessed with 0.25 µM
(A-B), 2.5 µM (C-D), and 25 µM (E-F) concentrations of Aß1-42. With the abundance of
molecules on a tissue surface, the MALDI MS spectra displayed poor S/N ratio with a
noisy baseline. Signal enhancement effects of Dynabead application was observed for each
concentration tested.
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5.3.2 Signal Enhancement Effects of Magnetic Beads for Amyloid Beta
Using MALDI MSI

Successful detection of Aß fragments and fibrils using MALDI MSI was previously
reported, but improvements are still needed to increase image resolution for MALDI MSI,
and to be able to detect intact Aß1-42 oligomers [24]. To achieve peak magnetic bead
extraction efficiency, sample preparatory protocols were first optimized. Salts and lipids
were first removed through serial tissue washes, but a balance must be attained to minimize
delocalization of target analytes, yet still effectively remove enough endogenous
contaminants for the detection of Aß. The ability to extract proteins from tissue sections
was dependent on suitable matrix application protocols. In order to facilitate efficient
extraction, a wet matrix application by means of an automated sprayer systems was used.
The solvent provides a medium for the extraction of analytes in order to co - crystallize
with the matrix for MALDI MS analysis. The spray parameters were tested and modified
to offer the ideal compromise allowing for the greatest degree of analyte extraction with
minimal levels of delocalization on the tissue surface. The choice of matrix used was also
a limiting factor. The matrix must be suitable for a higher mass range to accommodate for
the molecular weight of intact proteins, it must be soluble in organic/aqueous solvents, and
possess small, unchanging particle size in order to provide a uniform coating on sample
sections. Commonly used matrices are CHCA and SA. CHCA is generally applied when
studying lower molecular weight proteins (< 5000 Da). SA is generally used for the
investigation of proteins of >3500 Da, and therefore makes it more suitable for intact Aß
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analysis. Previously, optimization of magnetic bead parameters have been achieved with
CHCA due to its abilities to accommodate for a wide range of MW making it ideal for
testing bead binding capabilities for a broad range of MW analytes. With the focus now
switching to MALDI MSI of tissue sections, sinapinic acid (SA) was tested and revealed
comparable results for Dynabead extraction efficiency. The solvent used for SA possessed
the same organic : aqueous ratio of 50 : 50 and therefore would not alter elution capabilities.

MALDI MSI data was collected for Aß1-42 and Aß1-40 presented in Figure 5.6. Once
optimization and development of a suitable sample preparatory techniques in the tissue
washing, matrix application, and rehydration protocols were achieved, the images showed
dramatic improvements in Aß detection. Aß proteins were detected at the injection site for
both, Aß1-40 and Aß1-42 samples using MALDI MSI (n = 4, n = 2 respectively). As a result
of the high intensity signal at the injection site, anatomical features of the brain tissue were
suppressed. Images obtained from wildtype rat brains showed weak levels of Aß along the
visible length of the corpus callosum within the section, this was a result of the injection
site located at the corpus callosum, and the high permeability of this region.

Dynabeads were applied over the entire tissue section with an airbrush. Once dried,
additional matrix and solvent layers were applied using the TM sprayer to help facilitate
Aß extraction from the tissue section. From Figure 5.6, the MALDI MSI data obtained
from tissue sections with Dynabead application showed a severe decrease in signal
detection with only the injection site from the wildtype tissue with Aß1-42 injected visible.
The spatial resolution of the images were found to be completely compromised, with a
significant decrease in signal intensity.

172

In comparison to former MALDI MS analysis, the images did not correlate with the
previous data obtained regarding Dynabead signal extraction. This was speculated to be a
result of several contributing factors, including the aforementioned signal suppression
effects, and the decrease in signal resolution and mass accuracy experienced when analysis
is performed on the three-dimensional tissue sections. When an additional layer of beads
were sprayed onto the tissue surface, this enhanced the negative effects of the uneven tissue
surfaces. Although expected, the degree of impact this posed for the resulting image
surpassed expectations. Additionally, image acquisition requires several hours to complete,
within the vacuum system it is possible the beads detached, and fell off during the duration
of this time period. Furthermore, additional precautions may be required to prevent
potential Aß sample loss during the tissue washing procedures, and to increase extraction
efficiency from the bead to co-crystallize with the matrix applied.
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Figure 5.6 MALDI MSI of Aß1-40 and Aß1-42 tissue sections of wildtype and transgenic
rats reveals presence of the target protein within the injection sites (circled in the images
above). However, upon addition of C18 Dynabeads, enhancement effects were not
observed. On the contrary, signal intensity and spatial resolution were both severely
compromised.
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5.4 Conclusion
MALDI MSI has provides a platform for the localization of proteins and peptides within
intact tissue sections. However, contaminants on tissue surfaces strongly reduced signal
detection capabilities for Aß. The extraction power of C18 magnetic Dynabeads for Aß
proteins were clearly observed for bare plate and on tissue MALDI MS analysis. When
applied to MALDI MSI, a combination of factors including surface uniformity, and
extraction efficiency contributed towards the inability to attain additional signal
enhancement effects.

Future work should focus on uncovering alternative substrates with Aß extraction potential,
such as magnetic nanoparticles, and use of metal ions. Magnetic nanoparticles would aid
in minimizing the negative impact that Dynabeads exhibited on the surface uniformity of
samples analyzed. If successful, the magnetic properties of the nanoparticles would be
beneficial in retaining spatial resolution when rigorous forms of tissue clean – up are
utilized. Application of metal ions as a matrix could potentially eliminate the need for
alternative substrates for extraction purposes. Both Zn2+ and Cu2+ have been found to bind
to histidine residues of Aß proteins [25-26]. Additionally, both metals have been reported
effective as a matrix, either in oxide form (ZnO), or as a modification of standard matrices
(Cu-CHCA) [27-28]. If successful, not only will this technique benefit the field of
Alzheimer’s research, it will help uncover a range of analytes upon tissue sections that may
have previously gone unnoticed due to signal suppression effects.
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Chapter 6: Conclusions & Future Work
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6.1 Conclusions and Future Work
Mass spectrometry (MS) is an incredibly powerful technique that has become an essential
tool for the analysis of biological molecules and systems. Through the introduction of soft
ionization techniques ESI and MALDI, it became possible for MS to identify intact
proteins. MALDI MS offers a means to perform targeted and untargeted identification of
the molecular weight, and amino acid sequence for proteins in a complex mixture. Current
MALDI MS research has extended past its conventional analysis capabilities, and
introduced a new dimension to sample analysis. Development of MALDI MSI provided an
alternative platform for protein and peptide detection, where location information within
an intact tissue section can be found. This presented the opportunity to utilize MALDI MSI
to better understand biological systems, and disease pathology by simultaneously acquiring
information regarding multiple analytes within a sample.

Integration of MALDI MSI as a technique for biochemical imaging eradicates the
uncertainties that exists with stains and labels used in traditional imaging methodology
such as immunohistochemistry (IHC). This is pertinent in furthering research involving the
pathology of disease like AD. The uncertainties that reside in disease progression along
with the physical and chemical properties of the toxic Aß protein make it difficult to select
stains and labels with high specificity. Unfortunately, Aß1-42 is the most relevant factor
when discussing AD pathology, but its instability in aqueous conditions and its propensity
for aggregation makes Aß challenging to work with in laboratory settings. Therefore new
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technology in the detection of Aß would be greatly beneficial in the advancements of
research in this field.

The ability for MALDI MSI detection of peptides within complex tissue systems was first
assessed using a low molecular weight dipeptide, ZP1609. Within tissue sections, the
abundance of lipids and metabolites are readily ionizable, and therefore posed as a
hindrance for peptide analysis due to ion suppression effects. The importance of tissue
washing, acidification, and rehydration protocols was outlined in chapter 3. These tissue
preparatory steps facilitated the removal of excess salts and lipids in order to reduce the
suppression effects experienced by these contaminants when upon analysis. The addition
of an acidification protocol presented significant enhancement effects in both signal
detection and spatial resolution of the images acquired. Capabilities of MALDI MS as a
fast and sensitive method in the detection of Aß oligomers was presented in chapter 4 of
this thesis. This work presented MALDI MS as a label-free method for researchers to
quickly characterize in vitro multimeric Aß composition prior to additional
neurodegenerative studies.

Through MALDI MS analysis of Aß, and the development of successful MALDI MSI
tissue preparatory protocols for ZP1609, MALDI MS detection of Aß spiked on top of the
tissue surface was assessed. As expected, the protein presented difficulty ionizing and
desorbing off of the tissue section. Along with the challenges of ion suppression from salts
and lipids, detection sensitivity of the low abundance Aß proteins were greatly diminished.
Application of solid-phase extraction (SPE) techniques using magnetic beads facilitated
the extraction of Aß samples off of the tissue section. Once the matrix was applied onto the
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sample, Aß was able to successfully elute off of the beads and ionize providing signals of
greater intensity. The magntic beads were able to enhance signal detection of low
concentration Aß samples which were previously undetectable when pipet onto the tissue
section. However, when extraction capabilities were tested using MALDI MSI on tissue
samples injected with either Aß1-42 or Aß1-40, the results differed. The reduction in signal
detection and spatial resolution of images acquired after application of the magnetic beads
was hypothesized to be a result of the uneven tissue surface. When an additional layer of
magnetic beads were applied onto the tissue section, the detrimental effects of the
challenges experienced with the uneven surface of three dimentional tissues samples were
amplified. Additionally, image acquisition for MALDI MSI requires several hours, the
beads were speculated to potentially detach off of the MALDI sample plate during the
acquisition process within the vacuum environment.

The ability to perform solid-phase extraction of Aß prior to MALDI MSI analysis would
be greatly beneficial in the ex vivo detection of Aß and understanding its correlations with
AD pathology. Not only will these advancements aid AD research, it would be extremely
useful in assisting the improvement of MALDI MSI detection sensitivity for all low
abundant substances within tissue sections that may have previously gone unnoticed.
Therefore, future work would revolve around development of alternative substrates with
higher extraction potential, and better compatibility with MALDI MSI conditions. These
can include the use of magnetic nanoparticles, or investigating the binding capabilities of
Aß to metals such as zinc and copper ions.
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In comparison to previously used Dynabeads, magnetic nanoparticles would provide a
much smaller substrate for Aß extraction. The reduction in size will help to minimize the
unavoidable effects of variations in surface uniformity tissue samples exhibit. This
reduction will instead aid in generating a more even layer with fuller coverage of the entire
sample section. Retaining the magnetic properties provide an advantage when additional
tissue treatments and washes are require without compromising spatial resolution of
analyte distribution.

Alternatively, the binding capabilities of Aß to metals such as zinc and copper ions can be
exploited. Although Zn2+ levels in the extracellular regions of the brain are fairly limited,
Zn2+ concentrations in brain regions most greatly affected by AD such as the hippocampus,
amygdala, and cortex are relatively high [1-2]. Zn2+ bind to histidine residues on Aß
proteins and peptides forming both 1 : 1, and 3 : 1 zinc(II)-Aß complexes [3]. This
interaction induced rapid in vitro aggregation of Aß [2, 4-6]. Like zinc, Cu2+ was also found
to interact with Aß by binding to the histidine residues. However, it was reported to form
1 : 1 and potentially 2 : 1 Cu(II)-Aß complexes [7-8]. The binding capabilities of Aß to
metal ions provides a great opportunity to utilize this interaction to enhance detection
sensitivity. The use of metal ions Zn2+ and Cu2+ provide an added bonus in removing the
necessity for an additional substrate appication for SPE, since both copper and zinc have
been utilized successfully as either a modification to standard matrices (Cu-CHCA), or as
a stand alone matrix (ZnO) [9-10].
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